# Pfizer Inc: Form 10-Q for the period ended Jun 28, 2020

- Company: [Pfizer Inc](/companies/pfe.md) (CIK 78003)
- Form: 10-Q
- Filed: 2020-08-06
- Accepted by EDGAR: Aug 6, 2020, 20:10 ET
- Period: 2020-06-28
- Accession: 0000078003-20-000060
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/pfe-06282020x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-06-28.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-03-30 to 2020-06-28 | $11.80bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2020-01-01 to 2020-06-28 | $23.83bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-03-30 to 2020-06-28 | $2.28bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2020-01-01 to 2020-06-28 | $4.66bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2020-03-30 to 2020-06-28 | $3.03bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2020-01-01 to 2020-06-28 | $5.90bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2020-03-30 to 2020-06-28 | $372.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2020-01-01 to 2020-06-28 | $762.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-03-30 to 2020-06-28 | $519.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2020-01-01 to 2020-06-28 | $993.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-03-30 to 2020-06-28 | $3.43bn | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2020-01-01 to 2020-06-28 | $6.83bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-03-30 to 2020-06-28 | $0.61 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2020-01-01 to 2020-06-28 | $1.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-03-30 to 2020-06-28 | $0.62 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2020-01-01 to 2020-06-28 | $1.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-03-30 to 2020-06-28 | 5,619,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2020-01-01 to 2020-06-28 | 5,616,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2020-01-01 to 2020-06-28 | $6.69bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2020-01-01 to 2020-06-28 | $942.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2020-01-01 to 2020-06-28 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-06-28 | $1.80bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-06-28 | $46.42bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-06-28 | $177.93bn | us-gaap:Assets |
| Current liabilities | at 2020-06-28 | $32.72bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-06-28 | $113.37bn | us-gaap:Liabilities |
| Long-term debt | at 2020-06-28 | $50.53bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-06-28 | $1.48bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2020-06-28 | $10.66bn | us-gaap:CommercialPaper |
| Shareholders' equity | at 2020-06-28 | $64.34bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 240,437 characters.

### Introduction

See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout this MD&A. Our MD&A is provided in addition to the accompanying condensed consolidated financial statements and footnotes to assist readers in understanding Pfizer’s results of operations, financial condition and cash flows. All trademarks in this MD&A are the property of their respective owners. The MD&A is organized as follows:

|  |  |  |
| --- | --- | --- |
| ● | Overview of Our Performance, Operating Environment, Strategy and Outlook | Beginning on page 47 |
|  | This section provides information about the following: Our Business; Our Business Development Initiatives; our performance during the second quarter and first six months of 2020 and 2019; Our Operating Environment; The Global Economic Environment; Our Strategy; and Our Financial Guidance for 2020. |  |
| ● | Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions | Beginning on page 57 |
|  | This section discusses our disclosures for those accounting policies and estimates that we consider important in understanding our consolidated financial statements. |  |
| ● | Analysis of the Condensed Consolidated Statements of Income | Beginning on page 58 |
|  | This section includes the following sub-sections: |  |
|  | ○ Revenues by Operating Segment and Geography | Beginning on page 59 |
|  | This sub-section provides an overview of revenues by operating segment and geography as well as revenue deductions. |  |
|  | ○ Revenues––Selected Product Discussion | Beginning on page 64 |
|  | This sub-section provides an overview of several of our biopharmaceutical products. |  |
|  | ○ Product Developments––Biopharmaceutical | Beginning on page 69 |
|  | This sub-section provides an overview of important biopharmaceutical product developments. |  |
|  | ○ Costs and Expenses | Beginning on page 72 |
|  | This sub-section provides a discussion about our costs and expenses. |  |
|  | ○ Provision/(Benefit) for Taxes on Income | Beginning on page 75 |
|  | This sub-section provides a discussion of items impacting our tax provisions. |  |
|  | ○ Non-GAAP Financial Measure (Adjusted Income) | Beginning on page 75 |
|  | This sub-section provides a discussion of an alternative view of performance used by management. |  |
| ● | Analysis of Operating Segment Information | Beginning on page 81 |
|  | This section provides a discussion of the performance of each of our operating segments. |  |
| ● | Analysis of the Condensed Consolidated Statements of Cash Flows | Beginning on page 88 |
|  | This section provides an analysis of our cash flows for the first six months of 2020 and 2019. |  |
| ● | Analysis of Financial Condition, Liquidity and Capital Resources | Beginning on page 89 |
|  | This section provides an analysis of selected measures of our liquidity and of our capital resources as of June 28, 2020 and December 31, 2019, as well as a discussion of our outstanding debt and other commitments that existed as of June 28, 2020 and December 31, 2019. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer’s future activities. |  |
| ● | New Accounting Standards | Beginning on page 93 |
|  | This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted. |  |
| ● | Forward-Looking Information and Factors That May Affect Future Results | Beginning on page 93 |
|  | This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements presented in this MD&A. |  |

Certain amounts in this MD&A may not add due to rounding. All percentages have been calculated using unrounded amounts.

### OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK

### Our Business

We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture and distribution of healthcare products, including innovative medicines and vaccines. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us (Alliance revenues).

At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through July 31, 2019, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information about this operating structure, see Notes to Condensed Consolidated Financial Statements––*Note 14A. Segment, Geographic and Other Revenue Information: Segment Information* and the “Commercial Operations” section in Part I, Item 1, “Business” of our 2019

Form 10-K.

Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements.

The majority of our revenues come from the manufacture and sale of biopharmaceutical products. As explained more fully in our 2019 Form 10-K, the biopharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. These factors include, among others: the loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights, the ability to replenish innovative biopharmaceutical products, healthcare legislation, pipeline productivity, the regulatory environment, pricing and access pressures, product manufacturing and competition. We also face challenges as a result of the global economic environment. For additional information about these factors and challenges, see the “Our Operating Environment” and “The Global Economic Environment” sections of this MD&A and in our 2019 Financial Report and Part I, Item 1A, “Risk Factors” of our 2019 Form 10-K and Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.

The financial information included in our condensed consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the three and six months ended May 24, 2020 and May 26, 2019. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended June 28, 2020 and June 30, 2019.

References to operational variances in this MD&A pertain to period-over-period growth rates that exclude the impact of foreign exchange. The operational variances are determined by multiplying or dividing, as appropriate, our current period U.S. dollar results by the current period average foreign exchange rates and then multiplying or dividing, as appropriate, those amounts by the prior-year period average foreign exchange rates. Although exchange rate changes are part of our business, they are not within our control. Exchange rate changes, however, can mask positive or negative trends in the business; therefore, we believe presenting operational variances provides useful information to evaluate the results of our business.

### Our Business Development Initiatives

We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities. We continue to evaluate business development transactions that have the potential to strengthen our businesses and their capabilities, such as our acquisitions of Array, Therachon, Hospira, Medivation, Anacor and AstraZeneca’s small molecule anti-infectives business, as well as collaborations, and alliance and license agreements with other companies. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will advance our businesses.

Our significant recent business development activities include:

- Agreement with Valneva SE––On April 30, 2020, we signed an agreement to co-develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies. In June 2020, Valneva announced that the antitrust-related condition precedent was met and, consequently, the agreement became effective. VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 2C. Acquisition, Equity-Method Investment and Licensing Arrangements: Licensing Arrangements.*
- Agreement with BioNTech SE––On April 9, 2020, we signed a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage our broad expertise in vaccine R&D, regulatory capabilities, and global manufacturing and distribution network. We and BioNTech plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the U.S. and Europe across multiple sites. For additional information, including information regarding our COVID-19 vaccine development program, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––The Global Economic Environment” and “Product Developments—Biopharmaceutical” sections of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 2C. Acquisition, Equity-Method Investment and Licensing Arrangements: Licensing Arrangements.*
- Formation of a New Consumer Healthcare Joint Venture––On July 31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. The joint venture develops and markets brands in the oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health categories and is one of the world’s leading over-the-counter healthcare companies. Our financial results, and our Consumer Healthcare segment’s operating results, for the second quarter of 2019 reflect three months of Consumer Healthcare segment operations and for the first six months of 2019 reflect six months of Consumer Healthcare segment operations, while financial results for the second quarter and first six months of 2020 do not reflect any contribution from the Consumer Healthcare business. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 2B. Acquisition, Equity-Method Investment and Licensing Arrangements: Equity-Method Investment.*
- Agreement to Combine Upjohn with Mylan N.V.––On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun off to Pfizer’s shareholders and, immediately thereafter, combined with Mylan. Pfizer shareholders would own 57% of the combined new company, and former Mylan shareholders would own 43%. The transaction is expected to be tax free to Pfizer and Pfizer shareholders. The transaction was approved by Mylan’s shareholders in June 2020 and is anticipated to close in the fourth quarter of 2020, subject to customary closing conditions, including receipt of the remaining required regulatory approvals. In June 2020, Upjohn Inc. and Upjohn Finance B.V. (a wholly-owned subsidiary of Upjohn Inc.) completed privately placed debt offerings in connection with the transaction. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 7D. Financial Instruments: Long-Term Debt* and the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this MD&A. We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 30% has been incurred since inception and through the first six months of 2020. Such charges include costs and expenses related to separation of legal entities and anticipated transaction costs.

For a description of the more significant recent transactions through February 27, 2020, the filing date of our 2019 Form 10-K, see the “Our Business Development Initiatives” section of our 2019 Financial Report.

### Our Second Quarter 2020 and First Six Months of 2020 Performance

*Revenues* decreased $1.5 billion, or 11%, in the second quarter of 2020, compared to the same period in 2019, reflecting an operational decrease of $1.2 billion, or 9%, as well as an unfavorable impact of foreign exchange of $277 million, or 2%. Excluding the impact of the Consumer Healthcare transaction, revenues decreased 3% operationally, reflecting a 31% operational decline in our Upjohn business mainly due to the U.S. loss of exclusivity of Lyrica, which was partially offset by 6% operational growth in our Biopharma business. Excluding the impact of Lyrica in the U.S., Upjohn revenues declined 6% operationally. Revenues for the second quarter of 2020 included an estimated net unfavorable impact of approximately $500 million, or 4%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.

*Revenues* decreased $2.6 billion, or 10%, in the first six months of 2020, compared to the same period in 2019, reflecting an operational decrease of $2.1 billion, or 8%, as well as an unfavorable impact of foreign exchange of $411 million, or 2%. Excluding the impact of the Consumer Healthcare transaction, revenues decreased 2% operationally, reflecting a 34% operational decline in our Upjohn business mainly due to the U.S. loss of exclusivity of Lyrica, which was partially offset by 9% operational growth in our Biopharma business. Excluding the impact of Lyrica in the U.S., Upjohn revenues declined 11% operationally. Revenues for the first six months of 2020 included an estimated net unfavorable impact of approximately $350 million, or 1%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.

See the “Analysis of the Condensed Consolidated Statements of Income––Revenues by Operating Segment and Geography” section below for more information, including a discussion of key drivers of our revenue performance.

For worldwide revenues and revenues by geography, for selected products, see the discussion in the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A. For additional information regarding the primary indications or class of certain products, see Notes to Condensed Consolidated Financial Statements––*Note 14C. Segment, Geographic and Other Revenue Information: Other Revenue Information.*

#### Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income

The following provides an analysis of the decrease in *Income from continuing operations before provision/(benefit) for taxes on income* for the second quarter and first six months of 2020:

| (MILLIONS OF DOLLARS) | Three Months | Six Months |
| --- | ---: | ---: |
| Income from continuing operations before provision/(benefit) for taxes on income, for the three and six months ended June 30, 2019 | $4,141 | $8,463 |
| Unfavorable change in revenues | (1,463) | (2,552) |
| Favorable/(Unfavorable) changes: |  |  |
| Lower Cost of sales(a) | 295 | 351 |
| Lower Selling, informational and administrative expenses(b) | 481 | 947 |
| Higher Research and development expenses(c) | (290) | (311) |
| Lower Amortization of intangible assets(d) | 279 | 577 |
| Higher Restructuring charges and certain acquisition-related costs(e) | (478) | (500) |
| Higher net gains recognized during the period on equity-securities(f) | 696 | 331 |
| Lower business and legal entity alignment costs(f) | 137 | 256 |
| Lower asset impairment charges(f) | 10 | 160 |
| Non-recurrence of net losses on early retirement of debt(f) | — | 138 |
| Higher income from collaborations, out-licensing arrangements and sales of compound/product rights(f) | 78 | 111 |
| GSK Consumer Healthcare JV equity method income(f) | 126 | 92 |
| Higher net periodic benefit credits other than service costs(f) | 57 | 85 |
| Unfavorable change in the fair value of contingent consideration(f) | (5) | (89) |
| Higher net interest expense(f) | (23) | (84) |
| Non-recurrence of insurance recoveries related to Hurricane Maria in 2019 | (25) | (50) |
| All other items, net | (65) | (86) |
| Income from continuing operations before provision/(benefit) for taxes on income, for the three and six months ended June 28, 2020 | $3,953 | $7,838 |

(a) See the “Costs and Expenses––Cost of Sales” section of this MD&A.

(b) See the “Costs and Expenses––Selling, Informational and Administrative (SI&A) Expenses” section of this MD&A.

(c) See the “Costs and Expenses––Research and Development (R&D) Expenses” section of this MD&A.

(d) See the “Costs and Expenses––Amortization of Intangible Assets” section of this MD&A.

(e) See the “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A.

(f) See Notes to Condensed Consolidated Financial Statements––*Note 4. Other (Income)/Deductions—Net.*

For information on our tax provision and effective tax rate see the “Provision/(Benefit) for Taxes on Income” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 5. Tax Matters.*

### Our Operating Environment

### Industry-Specific Challenges

#### Intellectual Property Rights and Collaboration/Licensing Rights

The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face significantly increased generic competition over the next few years. For example, Lyrica lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019. Also, the basic product patent for Chantix in the U.S. will expire in November 2020. We expect the impact of reduced revenues due to patent expiries will be significant in 2020, then moderating downward to a much lower level from 2021 through 2025.

For additional information, including the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires and recent and expected losses of product exclusivity, see the “Patents and Other Intellectual Property Rights” section in Part I, Item 1, “Business” of our 2019 Form 10-K.

We will continue to aggressively defend our patent rights whenever we deem appropriate. For a discussion of certain recent developments with respect to patent litigation, see Notes to Condensed Consolidated Financial Statements––*Note 13A1. Contingencies and Certain Commitments: Legal Proceedings––Patent Litigation.*

#### Regulatory Environment/Pricing and Access––U.S. Healthcare Legislation

In March 2010, the ACA was enacted in the U.S. For additional information, see the “Government Regulation and Price Constraints” section in Part I, Item 1, “Business”, of our 2019 Form 10-K.

*We recorded the following amounts as a result of the U.S. Healthcare Legislation:*

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | Six Months Ended June 28, 2020 | June 30, 2019 |
| --- | ---: | ---: | ---: | ---: |
| Reduction to Revenues, related to the Medicare “coverage gap” discount provision | $216 | $154 | $350 | $289 |
| Selling, informational and administrative expenses, related to the fee payable to the federal government (which is not deductible for U.S. income tax purposes), based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs. | 71 | 70 | 110 | 121 |

#### Regulatory Environment/Pricing and Access––Government and Other Payer Group Pressures

The pricing of medicines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, medical services and hospital services, continues to be important to payers, governments, patients, and other stakeholders. Governments, MCOs and other payor groups continue to seek increasing discounts on our products through a variety of means and could have a material adverse impact on our results of operations. We believe that medicines are amongst the most powerful tools for patients in curing, treating and preventing illness and disability, and that all patients should have appropriate access to the medicines their doctors prescribe. We may consider a number of factors when determining a medicine’s price, including, for example, its impact on patients and their disease, other available treatments, the medicine’s potential to reduce other healthcare costs (such as hospital stays), and affordability. Within the U.S., in particular, we may also engage with patients, doctors and healthcare plans regarding their views. We also negotiate with insurers, including PBMs and MCOs, often providing significant discounts to them from the list price. The price that patients pay in the U.S. for the medicines their physicians prescribe is ultimately set by healthcare providers and insurers. On average, in the U.S., insurers impose a higher out-of-pocket burden on patients for prescription medicines than for comparably-priced medical services. Private third-party payers and federal and state governments in the U.S. continue to take action to manage the utilization of drugs and control the cost of drugs, including increasingly employing formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. For example, in July 2020, President Trump announced that he had signed four Executive Orders related to drug pricing, including orders addressing Part D rebate reform, the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, drug importation from Canada, and most favored nation pricing for Medicare. We will continue to work with insurance providers, governments and others to improve access to today’s innovative treatments. Certain governments, including the different EU member states, the U.K., China, Japan, Canada, South Korea and some other international markets, provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global financing pressures. Governments may use a variety of cost-containment measures for our pharmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, “international reference pricing” (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement.

In China, a centralized VBP program was initiated in 2018. Under this procurement model, a tender process has been established where a certain portion of included molecule volumes are guaranteed to tender winners. The program is intended to contain healthcare costs by driving utilization of generics that have passed quality consistency evaluation, which has resulted in dramatic price cuts for off-patent medicines. Upjohn and most off-patent originators were not successful in the first bidding process under this pilot, which was finalized in December 2018 and implemented in March 2019, and most contracts went to local generic companies. This pilot program covered 25 molecules, including atorvastatin calcium tablets (Lipitor) and amlodipine besylate tablets (Norvasc). In April 2020, China implemented another round of expansion of the national VBP program, which covers 33 new molecules, including Biopharma’s Zithromax tablets and Diflucan capsules and no Upjohn products. Biopharma was not successful in the bidding process for this expansion. In June 2020, China announced the latest round of the expansion of the VBP program, which is expected to be implemented in November 2020 and includes Biopharma’s Xeljanz and Zyvox tablets and Upjohn’s Viagra, Zoloft and Celebrex.

For additional information, see the “Government Regulation and Price Constrains” section in Part I, Item 1, “Business” of our 2019 Form 10-K.

#### Other Industry-Specific Challenges

Regulatory agencies periodically inspect our drug manufacturing facilities to evaluate compliance with cGMP or other applicable requirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, recall of a product, delays or denials of product approvals, import bans or denials of import certifications, any of which could have a material adverse effect on our business, financial condition and results of operations. In December 2019-January 2020, for example, the FDA conducted an inspection of our McPherson facility and issued an inspection report noting several findings to which Pfizer responded. Based on the outcome of this inspection, the FDA upgraded the inspection classification of the McPherson site to Voluntary Action Indicated (VAI) from Official Action Indicated. VAI status will allow supplements, including those for manufacturing changes/improvements and new products, to proceed for approval following the normal FDA process for a site with an acceptable compliance status. For additional information, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––Industry-Specific Challenges––Product Manufacturing” section of our 2019 Financial Report.

We and other pharmaceutical companies continue to face industry-specific challenges that can significantly impact our business, including, among others, the regulatory environment, pipeline productivity, product manufacturing and competition. For additional information, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––Industry-Specific Challenges––Regulatory Environment––Pipeline Productivity”, “––Product Manufacturing” and “––Competition” sections of our 2019 Financial Report and Part I, Item 1A, “Risk Factors” of our 2019 Form 10-K and Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.

### The Global Economic Environment

In addition to the industry-specific factors discussed above, we, like other businesses of our size, are exposed to the economic cycle, which impacts our biopharmaceutical operations globally.

***COVID-19 Pandemic.*** In December 2019, illnesses associated with COVID-19 were reported and the virus has since caused widespread and significant disruptions to daily life and economies across geographies. The World Health Organization has classified the outbreak as a pandemic. Our business, operations and financial condition and results have been impacted to varying degrees, primarily during the second quarter of 2020. We currently anticipate an ongoing, gradual global recovery from the first-half 2020 macroeconomic and healthcare impacts of the COVID-19 pandemic. For additional information on the impact of COVID-19 on our revenues, please see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Second Quarter 2020 and First Six Months of 2020 Performance” section of this MD&A.

### Pfizer’s Response to COVID-19

We are fully committed to confronting the public health challenge posed by the COVID-19 pandemic by collaborating with industry partners and academic institutions to develop potential approaches to prevent and treat COVID-19. Our researchers and scientists also have been exploring potential new uses of existing medicines in our portfolio that may be able to help infected patients.

In response to the COVID-19 pandemic, in March 2020, we issued a five-point plan calling on the biopharmaceutical industry to join us in committing to unprecedented collaboration to combat COVID-19. Subsequently, we announced some important advances in the battle against the COVID-19 pandemic, including, among others:

- We and The Pfizer Foundation announced the commitment of $40 million in medical and charitable cash grants to help combat the health effects of the COVID-19 pandemic in the U.S. and around the world. The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
- We confirmed a lead compound and analogues in our portfolio are potent inhibitors of the SARS-CoV-2 3C-like protease, based on the results of initial screening assays. In addition, preliminary data suggest the lead protease inhibitor shows antiviral activity against SARS-CoV-2, the virus that causes COVID-19. Consequently, we are continuing to perform pre-clinical confirmatory studies, including further anti-viral profiling and assessment of the suitability of the lead molecule for IV administration clinically. In July 2020, we published the chemical structure of a 3C-like (3CL) protease inhibitor and its in vitro activity against coronaviruses, including SARS-CoV-2. In parallel, we are also investing in materials with the aim of accelerating the start of a potential clinical study of the lead molecule to the third quarter of 2020, subject to positive completion of the pre-clinical confirmatory studies and regulatory approval.
- We entered into a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. As part of this co-development program, which we refer to as Project Lightspeed, we and BioNTech announced in July 2020 the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA candidate. After extensive review of preclinical and clinical data from Phase 1/2 clinical trials, and in consultation with the FDA’s Center for Biologics Evaluation and Research and other global regulators, we and BioNTech chose to advance the BNT162b2 vaccine candidate into the Phase 2/3 study, at a 30 µg dose level in a 2 dose regimen. BNT162b2, which received Fast Track designation from the FDA in July 2020, encodes an optimized SARS-CoV-2 full length spike glycoprotein, which is the target of virus neutralizing antibodies. If the Phase 2/3 trial is successful, we and BioNTech expect to be ready to seek Emergency Use Authorization or some form of regulatory approval as early as October 2020. If authorization or approval is obtained, the companies currently aim to supply globally (excluding China) up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021. Also in July and August 2020, we and BioNTech announced agreements with the following governments: (i) with the U.K. government for 30 million doses of BNT162, to be delivered in 2020 and 2021, subject to clinical success and regulatory approval or authorization; (ii) with the U.S. government, under which the U.S. government will pay $1.95 billion, in installments as vaccine quantities are delivered, for the first 100 million doses of BNT162, subject to regulatory approval or Emergency Use Authorization from the FDA, as well as the ability for the U.S. government to acquire up to an additional 500 million doses; (iii) with the government of Japan to supply 120 million doses of BNT162, subject to clinical success and regulatory approval, beginning in 2021; and (iv) with the government of Canada to supply BNT162, subject to clinical success and Health Canada approval, over the course of 2021. For additional information on our collaboration with BioNTech, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business Development Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 2C. Acquisition, Equity-Method Investment and Licensing Arrangements: Licensing Arrangements.*

Despite our significant investments and efforts, our development programs for any potential treatment or vaccine for COVID-19 may not be successful as the risk of failure is significant and there can be no certainty these efforts will yield a successful product or that these costs will ultimately be recouped. In addition, we may change the way we approach or provide additional research funding for potential drug and/or vaccine development related to COVID-19. We will continue to share information from our research that could benefit the global effort to respond to this unprecedented healthcare crisis.

### Impact of COVID-19 on Pfizer’s Business and Operations

We are continuing to monitor the latest developments regarding the COVID-19 pandemic on our business, operations, and financial condition and results, and have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration and severity of the pandemic and the global macroeconomic impact of the pandemic. For additional information, please also see our financial guidance set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Financial Guidance for 2020” section of this MD&A. Despite careful tracking and planning, however, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. In particular, we believe the ultimate impact on our business, operations and financial condition and results will be affected by the speed and extent of the continued spread of the coronavirus globally, the duration of the pandemic, new information that may emerge concerning the severity and incidence of COVID-19, the safety, efficacy and availability of a vaccine and treatments for COVID-19, the global macroeconomic impact of the pandemic and governmental or regulatory actions to contain the virus or control supply of medicines. We are focused on all aspects of our business and are implementing measures aimed at mitigating issues where possible, including by using digital technology to assist in operations for our commercial, manufacturing, R&D and enabling functions globally.

- *Our Colleagues.* Our colleagues and customers have both experienced disruptions to the normal ways of working. At this time, our colleagues in most locations who are able to perform their job functions outside of our facilities continue to work remotely. Certain of our colleagues, primarily those in the Pfizer Global Supply and Worldwide Research and Development organizations, have roles for which their physical presence at our facilities is required to perform their job functions. These colleagues continue to report to work and are subject to strict protocols intended to reduce the risk of transmission, including social distancing, maintaining contact logs, increased cleaning and use of personal protective equipment as necessary.
- *Our Sales and Marketing.* We have experienced an impact on our sales and marketing activities due to widespread restrictions on in-person meetings with healthcare professionals and the refocused attention of the medical community on fighting COVID-19. Access to prescribers for sales force colleagues during the second quarter of 2020 was mixed, with those in most international markets able to meet with healthcare professionals for most of the quarter, while those in the U.S. were unable to meet in-person with healthcare professionals for nearly all of the quarter. At this time, no U.S. sales force colleagues are meeting in-person with healthcare professionals due to COVID-19-related safety concerns. We are actively reviewing and assessing epidemiological data and our colleagues remain ready to resume in-person engagements with healthcare professionals on a location-by-location basis as soon as it is safe to do so.

As a result of the lower number of in-person meetings with prescribers and restrictions on patient movements due to government-mandated work-from-home or shelter-in-place policies, the rate of new prescriptions for certain products and of vaccination rates for most vaccines slowed in certain markets, which negatively impacted our second quarter 2020 financial results. These declines were partially offset by certain of our medicines and vaccines that saw increased demand in certain markets compared to the prior-year quarter, including Prevenar 13 for *streptococcus pneumoniae* in adults in international markets as well as certain sterile injectable products utilized in the intubation and ongoing treatment of mechanically-ventilated COVID-19 patients.

During the pandemic, we have adapted our promotional platform by amplifying our existing digital capabilities to reach healthcare professionals and customers to provide critical education and information, including increasing the scale of our remote engagement. All of our U.S. sales representatives are digitally enabled, and we are currently conducting virtual detailing and remote sampling, which has proven to be an efficient way to interact with healthcare providers during the crisis.

- *Our Manufacturing and Supply Chain.* Our manufacturing and supply chain professionals have been working continuously in an effort to ensure continued patient access to our medicines and vaccines. Across our plant network, we have implemented our preparedness plan to control site operations. To date, we have not seen a significant disruption in our supply chain, and all of our manufacturing sites around the world have continued to operate at or near normal levels. So far, we have been able to mitigate distribution issues that have arisen, including by using newly available excess capacity in commercial airplanes to transport inventory. In addition, we have taken steps to scale up manufacturing operations at risk to accelerate our ability to supply a potential novel treatment or potential vaccine for COVID-19 if we receive regulatory approval. We are also committed to offering any excess manufacturing capacity and to potentially shifting production in order to support others’ efforts to manufacture any lifesaving breakthroughs that may be developed to combat COVID-19.
- *Our Clinical Trials.* After a brief pause to the recruitment portion of certain ongoing clinical studies and a delay to most new study starts, in late-April 2020 we restarted recruitment across the development portfolio, including new study starts. We continue to work closely with clinical trial sites to understand their needs and are performing remote monitoring, where appropriate, to oversee study conduct. In addition, processes to enable tele-health and home healthcare are being utilized where appropriate to continue the data collection process and support patient safety.
- *Our Products.* Our portfolio of products comprises medicines and vaccines which may experience varying impacts from the COVID-19 pandemic. Some of our products, such as Eliquis and Ibrance, are medically necessary but also more reliant on maintenance therapy with continuing patients in addition to new patients. Certain other products, such as Vyndaqel/Vyndamax, Chantix/Champix and products used in certain elective surgeries, are more reliant on new patient starts and typically require doctor visits, including wellness visits. Other medicines have been identified as medically necessary for treatment in the pandemic, such as certain of our Hospital sterile injectable products. A large proportion of our portfolio comprises oral or self-injected medicines that do not require a visit to an infusion center or a physician’s office for administration, but vaccines and physician-administered medicines which do require office visits were impacted by COVID-19-related mobility restrictions or limitations during the second quarter of 2020. Specialty pharmacy channels, from which we derive a majority of our revenue, enable direct delivery of these specialty medicines to patients.
- *Our Financial Condition and Access to Capital Markets.* Due to our significant operating cash flows, as well as our financial assets, access to capital markets and revolving credit agreements, we believe we have, and will maintain, the ability to meet liquidity needs for the foreseeable future.

We will continue to pursue efforts to maintain the continuity of our operations while monitoring for new developments related to the COVID-19 pandemic, which are unpredictable. Future COVID-19 developments could result in additional favorable or unfavorable impacts on our business, operations or financial condition and results. If we experience significant disruption in our manufacturing or supply chains or significant disruptions in clinical trials or other operations, or if demand for our products is ultimately significantly reduced as a result of the COVID-19 pandemic, we could experience a material adverse impact on our business, operations and financial condition and results. For additional information, please also see Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.

For other global economic environment matters impacting our business, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––The Global Economic Environment” section of our 2019 Financial Report.

These and other industry-wide factors that may affect our businesses should be considered along with information presented in the “Forward-Looking Information and Factors That May Affect Future Results” section of this MD&A and in Part I, Item 1A, “Risk Factors” of our 2019 Form 10-K and Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.

### Our Strategy

We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our Company’s purpose: *Breakthroughs that change patients’ lives*. By doing so, we expect to create value for the patients we serve and for our colleagues and shareholders. For a more comprehensive discussion of our strategy including additional discussion of certain items below, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy” section of our 2019 Financial Report.

#### Organizing for Growth

We believe we have one of the strongest pipelines we have had in over a decade, and believe we are well positioned for future growth. Additional patent expiries will continue over several years, and we expect the impact of reduced revenues due to patent expiries will be significant in 2020, then moderating downward to a much lower level from 2021 through 2025. This confluence of events has provided us an opportunity to look at and refine how we organize our business to best achieve sustainable growth and to deliver our medicines and vaccines to the maximum number of people who need them.

At the beginning of our fiscal year 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each led by a single manager—Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through July 31, 2019, Pfizer’s Consumer Healthcare business. We designed this new global structure to take advantage of new growth opportunities driven by the evolving and unique dynamics of relevant markets. For additional information about each business, see Notes to Condensed Consolidated Financial Statements—*Note 14A. Segment, Geographic and Other Revenue Information: Segment Information.* As part of our Organizing for Growth initiative, we also reorganized our R&D operations, as explained in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy––Organizing for Growth” section of our 2019 Financial Report.

Subsequent to the re-alignment of our commercial operations in 2019, on July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. For additional information, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business Development Initiatives” section above in this MD&A. We believe the new company will transform and accelerate Upjohn’s and Mylan’s ability to serve patients’ needs and expand their capabilities across more than 165 markets. The combination will drive a sustainable, diverse and differentiated portfolio of prescription medicines, complex generics, over-the-counter products and biosimilars supported by commercial and regulatory expertise, established infrastructure, R&D capabilities and manufacturing and supply chain excellence.

As we prepare for expected growth, we are focused on creating a simpler, more efficient organization by streamlining structures, processes and governance within each business and the functions that support them. As our innovative pipeline matures based on anticipated progression of current trials and the initiation of new pivotal trials, including new trials for medicines we may acquire or in-license, we will need to increase our R&D investments. In addition, as our pipeline potentially delivers new commercialization opportunities, we will need to increase our investments in new-market-creation activities. We have initiated an enterprise-wide digital effort to accelerate drug development, enhance experiences (patient and physician) and access and leverage technology and robotics to simplify and automate our processes.

#### Transforming to a More Focused Company

With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines. As a result, we began, in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base, which is expected to be 20% less (based on the midpoint of the range for 2020 New Pfizer revenue guidance, compared to 2019 Total Company reported revenue) as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions. While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&D, Manufacturing and Commercial. For additional information, see the “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A.

### Our Financial Guidance for 2020

On July 28, 2020, we increased our 2020 financial guidance for Total Company and New Pfizer revenues and Adjusted diluted EPS and reaffirmed all other financial guidance components.

The guidance reflects management’s current expectations for operational performance, foreign exchange rates as well as various COVID-19-related uncertainties, primarily those related to the severity, duration and global macroeconomic impact of the pandemic. Key guidance assumptions regarding these uncertainties broadly reflect an ongoing, gradual global recovery from the first half of 2020 macroeconomic and healthcare impacts of the COVID-19 pandemic. Specific COVID-19-related assumptions include:

- Patient visits with physicians, vaccination rates and the number of elective surgical procedures will gradually increase from second-quarter 2020 levels, beginning in the third quarter of 2020;
- New-to-brand prescription trends for certain key products will gradually improve from second-quarter 2020 levels, beginning in the third quarter of 2020;
- Gradual improvement in access to U.S. healthcare professionals for sales force colleagues;
- Clinical trial enrollment, including new study starts, continues throughout the remainder of 2020;
- Pfizer’s manufacturing and supply chain activities continue to not be materially disrupted; and
- Pfizer’s investments in potential treatments and a potential vaccine for COVID-19 continue throughout 2020.

However, updated financial guidance does not include any revenues from a potential COVID-19 vaccine.

Based on results to date and these assumptions for the remainder of the year, Pfizer increased its 2020 financial guidance for Total Company revenues and Adjusted diluted EPS and reaffirmed all other Total Company financial guidance components.

|  |  |
| --- | --- |
| Pfizer’s updated 2020 financial guidance is presented below(a), (b): |  |
| Revenues | $48.6 to $50.6 billion |
|  | (previously $48.5 to $50.5 billion) |
| Adjusted cost of sales as a percentage of revenues | 19.5% to 20.5% |
| Adjusted selling, informational and administrative expenses | $11.5 to $12.5 billion |
| Adjusted research and development expenses | $8.6 to $9.0 billion |
| Adjusted other (income)/deductions | Approximately $800 million of income |
| Effective tax rate on adjusted income | Approximately 15.0% |
| Adjusted diluted EPS | $2.85 to $2.95 |
|  | (previously $2.82 to $2.92) |

(a) The 2020 financial guidance reflects the following:

- Financial guidance for Total Company reflects a full-year 2020 contribution from Biopharma and Upjohn, the current construct of the company, and excludes any impact from the pending Upjohn combination with Mylan.
- Does not assume the completion of any business development transactions not completed as of June 28, 2020, including any one-time upfront payments associated with such transactions.
- Includes Pfizer’s pro rata share of the GSK Consumer Healthcare joint venture anticipated earnings, which is recorded in Adjusted other (income)/deductions on a one-quarter lag. Therefore, 2020 financial guidance for Adjusted other (income)/deductions and Adjusted diluted EPS reflects Pfizer’s share of the joint venture’s earnings that were generated in the fourth quarter of 2019 and in the first quarter of 2020 (recorded by Pfizer in the first six months of 2020) as well as Pfizer’s share of the joint venture’s projected earnings during the second and third quarters of 2020.
- Reflects an anticipated negative revenue impact of $2.4 billion due to recent and expected generic and biosimilar competition for certain products that have recently lost or are anticipated to soon lose patent protection.
- Exchange rates assumed are a blend of actual exchange rates in effect through second-quarter 2020 and mid-July 2020 rates for the remainder of the year. Financial guidance reflects the anticipated unfavorable impact of approximately $0.6 billion on revenues and approximately $0.05 on Adjusted diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2019.
- Guidance for adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.6 billion shares, which assumes no share repurchases in 2020.

(b) For an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A.

Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in Pfizer’s Upjohn business beginning in the first quarter of 2020.

Pfizer, Upjohn and Mylan agreed (simultaneous with their entry into the transaction agreements governing the proposed combination of Upjohn and Mylan) to review and negotiate in good faith a potential transfer of Pfizer’s Meridian Medical Technologies business (the Meridian Business) to Upjohn, such that it would be sold to Mylan in the pending transaction for the Upjohn business. The Meridian Business supplies EpiPen Auto-Injectors to Mylan under a supply agreement expiring December 31, 2020 (the EpiPen Supply Agreement). Instead of entering into an agreement to transfer the Meridian Business to Mylan, the parties have agreed to extend the EpiPen Supply Agreement for an additional four-year period through December 31, 2024, with an option for Mylan to further extend the term for an additional one-year period thereafter.

Pfizer and Mylan have also reached a preliminary agreement on the general terms under which Pfizer would transfer certain Pfizer assets that currently form part of the Mylan-Japan collaboration to Mylan or, following the proposed combination of Upjohn and Mylan, to Viatris. Any such proposed transaction would be subject to the finalization and execution of a definitive agreement that would contain customary closing conditions, including but not limited to, receipt of any necessary regulatory approvals. There can be no assurance that any agreement or transaction will result from these negotiations, and if the parties are unsuccessful in their efforts to negotiate the terms of such potential transactions, the Pfizer assets that currently form part of the Mylan-Japan collaboration will remain with Pfizer.

### 2020 Financial Guidance for New Pfizer

|  |  |
| --- | --- |
| 2020 updated financial guidance for New Pfizer is presented below(a), (b): |  |
| Revenues | $40.8 to $42.4 billion |
|  | (previously $40.7 to $42.3 billion) |
| Adjusted IBT Margin(c) | Approximately 37.0% |
| Adjusted Diluted EPS | $2.28 to $2.38 |
|  | (previously $2.25 to $2.35) |
| Operating Cash Flow(d) | $10.0 to $11.0 billion |

(a) The financial guidance for New Pfizer reflects a full-year 2020 view of the company assuming the pending Upjohn combination with Mylan was completed at the beginning of 2020 and reflects contributions from the Biopharma business as it is presently being managed, which excludes contributions from Pfizer’s Meridian subsidiary and the Pfizer-Mylan strategic collaboration in Japan (Mylan-Japan). Pfizer’s Meridian subsidiary and Mylan-Japan were managed by Pfizer’s Biopharma business in 2019, but were moved to Upjohn in 2020. Financial guidance for New Pfizer also includes the full-year effect of the following items that assume the completion of the Upjohn combination with Mylan: (i) $12 billion of net proceeds from Upjohn to be retained by Pfizer, which Pfizer will use to repay its own existing indebtedness; and (ii) other transaction-related items, such as income from transition services agreements between Pfizer and Viatris. In addition, 2020 financial guidance for New Pfizer Adjusted IBT Margin and Adjusted diluted EPS reflects Pfizer’s share of the GSK Consumer Healthcare joint venture’s earnings that were generated in the fourth quarter of 2019 and in the first quarter of 2020 (recorded by Pfizer in the first six months of 2020), as well as Pfizer’s share of the GSK Consumer Healthcare joint venture’s projected earnings during the second and third quarters of 2020.

(b) For additional information regarding an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A.

(c) Adjusted income before tax margin (Adjusted IBT margin) is defined as revenue less the sum of Adjusted cost of sales, Adjusted SI&A expenses, Adjusted R&D expenses, Adjusted amortization of intangible assets and Adjusted other (income)/deductions as a percentage of revenue. Adjusted IBT margin is presented because management believes this performance measure supplements investors’ and other readers’ understanding and assessment of the financial performance of New Pfizer. Adjusted IBT margin is not, and should not be viewed as, a substitute for U.S. GAAP income before tax margin.

(d) Includes a $1.25 billion voluntary contribution to the U.S. qualified pension plans, planned for the second half of 2020.

### 2020 Financial Guidance for Upjohn

|  |  |
| --- | --- |
| 2020 reaffirmed financial guidance for Upjohn is presented below(a): |  |
| Revenues | $8.0 to $8.5 billion |
| Adjusted EBITDA(b) | $3.8 to $4.2 billion |

(a) Financial guidance for Upjohn reflects a full-year 2020 contribution from the Upjohn business as it is presently being managed, which includes contributions from Pfizer’s Meridian subsidiary and the Pfizer-Mylan strategic collaboration in Japan (Mylan-Japan). Pfizer’s Meridian subsidiary and Mylan-Japan were managed by Pfizer’s Biopharma business in 2019 but were moved to Upjohn in 2020.

(b) Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) is defined as reported U.S. GAAP net income, and its components, adjusted for interest expense, provision for taxes on income and depreciation and amortization, further adjusted to exclude purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items (some of which may recur, such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on equity securities, but which management does not believe are reflective of ongoing core operations). Adjusted EBITDA is presented because management believes this performance measure supplements investors’ and other readers’ understanding and assessment of the financial performance of Upjohn. Adjusted EBITDA as defined is not a measurement of financial performance under GAAP, and should not be considered as an alternative to net income or cash flow from operations determined in accordance with GAAP.

Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-related expenses, gains and losses from equity securities and potential future asset impairments without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.

For information about our actual costs and anticipated costs and cost savings associated with our Transforming to a More Focused Company program, see the “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

Our 2020 financial guidance is subject to a number of assumptions, as well as factors and uncertainties as described in the “Our Operating Environment”, “The Global Economic Environment”, “Our Strategy” and “Forward-Looking Information and Factors That May Affect Future Results” sections of this MD&A; Part I, Item 1A, “Risk Factors” of our 2019 Form 10-K, and Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.

### SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS

For a description of our significant accounting policies, see Notes to Consolidated Financial Statements––*Note 1. Basis of Presentation and Significant Accounting Policies* in our 2019 Financial Report. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (Note 1D); Fair Value (Note 1E); Revenues (Note 1G); Asset Impairments (Note 1L); Tax Assets and Liabilities and Income Tax Contingencies (Note 1P); Pension and Postretirement Benefit Plans (Note 1Q); and Legal and Environmental Contingencies (Note 1R).

For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the “Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions” section of our 2019 Financial Report. See also Notes to Consolidated Financial Statements––*Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions* in our 2019 Financial Report for a discussion about the risks associated with estimates and assumptions.

For a discussion of recently adopted accounting standards and significant accounting policies, see Notes to Condensed Consolidated Financial Statements––*Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2020* and *Note 1C. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable.*

### ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME

*The following table provides the components of the condensed consolidated statements of income:*

| (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $11,801 | $13,264 | (11) | $23,829 | $26,382 | (10) |
| Cost of sales(a) | 2,281 | 2,576 | (11) | 4,658 | 5,009 | (7) |
| % of revenues | 19.3% | 19.4% |  | 19.5% | 19.0% |  |
| Selling, informational and administrative expenses(a) | 3,030 | 3,511 | (14) | 5,903 | 6,850 | (14) |
| % of revenues | 25.7% | 26.5% |  | 24.8% | 26.0% |  |
| Research and development expenses(a) | 2,132 | 1,842 | 16 | 3,856 | 3,544 | 9 |
| % of revenues | 18.1% | 13.9% |  | 16.2% | 13.4% |  |
| Amortization of intangible assets | 905 | 1,184 | (24) | 1,790 | 2,367 | (24) |
| % of revenues | 7.7% | 8.9% |  | 7.5% | 9.0% |  |
| Restructuring charges and certain acquisition-related costs | 362 | (115) | \* | 431 | (69) | \* |
| % of revenues | 3.1% | (0.9)% |  | 1.8% | (0.3)% |  |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | (6) | — | \* |
| % of revenues | — | — |  | — | — |  |
| Other (income)/deductions––net | (862) | 126 | \* | (641) | 218 | \* |
| Income from continuing operations before provision/(benefit) for taxes on income | 3,953 | 4,141 | (5) | 7,838 | 8,463 | (7) |
| % of revenues | 33.5% | 31.2% |  | 32.9% | 32.1% |  |
| Provision/(benefit) for taxes on income | 519 | (915) | \* | 993 | (481) | \* |
| Effective tax rate | 13.1% | (22.1)% |  | 12.7% | (5.7)% |  |
| Income from continuing operations | 3,434 | 5,056 | (32) | 6,845 | 8,945 | (23) |
| % of revenues | 29.1% | 38.1% |  | 28.7% | 33.9% |  |
| Discontinued operations––net of tax | — | — | — | — | — | — |
| Net income before allocation to noncontrolling interests | 3,434 | 5,056 | (32) | 6,845 | 8,945 | (23) |
| % of revenues | 29.1% | 38.1% |  | 28.7% | 33.9% |  |
| Less: Net income attributable to noncontrolling interests | 8 | 10 | (19) | 17 | 15 | 10 |
| Net income attributable to Pfizer Inc. | $3,426 | $5,046 | (32) | $6,828 | $8,929 | (24) |
| % of revenues | 29.0% | 38.0% |  | 28.7% | 33.8% |  |
| Earnings per common share––basic: |  |  |  |  |  |  |
| Income from continuing operations attributable to Pfizer Inc. common shareholders | $0.62 | $0.91 | (32) | $1.23 | $1.59 | (23) |
| Net income attributable to Pfizer Inc. common shareholders | $0.62 | $0.91 | (32) | $1.23 | $1.59 | (23) |
| Earnings per common share––diluted: |  |  |  |  |  |  |
| Income from continuing operations attributable to Pfizer Inc. common shareholders | $0.61 | $0.89 | (31) | $1.22 | $1.56 | (22) |
| Net income attributable to Pfizer Inc. common shareholders | $0.61 | $0.89 | (31) | $1.22 | $1.56 | (22) |

\* Indicates calculation not meaningful or result is equal to or greater than 100%.

(a) Excludes amortization of intangible assets, except as disclosed in Notes to Condensed Consolidated Financial Statements––*Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.*

### Revenues by Operating Segment and Geography

The following graphs show revenues by operating segment and geography:

### Second Quarter

| 2020 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 46% |
| International | 54% |

| 2019 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 48% |
| International | 52% |

### First Six Months

| 2020 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 46% |
| International | 54% |

| 2019 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 47% |
| International | 53% |

59

*The following tables provide worldwide revenues by operating segment and geography:*

| (MILLIONS OF DOLLARS) Operating Segments(a): | Three Months Ended Worldwide June 28, 2020 June 30, 2019 | U.S. June 28, 2020 June 30, 2019 | International June 28, 2020 June 30, 2019 | World-wide U.S. Inter-national % Change in Revenues |
| --- | ---: | ---: | ---: | ---: |
| Biopharma | $9,795 $9,432 | $5,045 $4,667 | $4,750 $4,765 | 4 8 — |
| Upjohn | 2,006 2,970 | 357 1,245 | 1,648 1,725 | (32) (71) (4) |
| Consumer Healthcare | — 862 | — 423 | — 439 | (100) (100) (100) |
| Total revenues | $11,801 $13,264 | $5,402 $6,335 | $6,399 $6,929 | (11) (15) (8) |
|  | Six Months Ended |  |  |  |
|  | Worldwide | U.S. | International | World-wide U.S. Inter-national |
| (MILLIONS OF DOLLARS) | June 28, 2020 June 30, 2019 | June 28, 2020 June 30, 2019 | June 28, 2020 June 30, 2019 | % Change in Revenues |
| Operating Segments(a): |  |  |  |  |
| Biopharma | $19,802 $18,477 | $10,258 $9,128 | $9,544 $9,349 | 7 12 2 |
| Upjohn | 4,027 6,184 | 795 2,518 | 3,232 3,666 | (35) (68) (12) |
| Consumer Healthcare | — 1,721 | — 864 | — 857 | (100) (100) (100) |
| Total revenues | $23,829 $26,382 | $11,053 $12,510 | $12,776 $13,872 | (10) (12) (8) |

(a) For additional information about each operating segment, see the “Analysis of Operating Segment Information” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 14A. Segment, Geographic and Other Revenue Information: Segment Information.*

#### Second Quarter of 2020 vs. Second Quarter of 2019

*The following provides an analysis of the worldwide change in revenues by geographic areas in the second quarter of 2020:*

| (MILLIONS OF DOLLARS) Operational growth/(decline): | Three Months Ended June 28, 2020 Worldwide | U.S. | International |
| --- | ---: | ---: | ---: |
| Continued growth from certain key brands(a) | $351 | $192 | $159 |
| Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU | 175 | 128 | 47 |
| Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC | 93 | 72 | 21 |
| Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit and new product launches | 78 | 55 | 23 |
| Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019 | 64 | 64 | — |
| Growth in revenues for Lipitor and Norvasc, reflecting significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion | 55 | 10 | 45 |
| Lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK. As a result, for the second quarter of 2019, revenues reflect three months of Consumer Healthcare segment operations, while for the second quarter of 2020, there is no contribution from the Consumer Healthcare business | (862) | (423) | (439) |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019 | (826) | (784) | (42) |
| Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Japan and Brazil, all of which is expected to continue | (66) | — | (66) |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition | (34) | (33) | (1) |
| Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China | (28) | (132) | 103 |
| Other operational factors, net | (185) | (82) | (103) |
| Operational growth/(decline), net | (1,186) | (933) | (253) |
| Unfavorable impact of foreign exchange | (277) | — | (277) |
| Revenues decrease | $(1,463) | $(933) | $(530) |

(a) Certain key brands represent Ibrance, Eliquis and Xeljanz. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Revenues for the second quarter of 2020 included an estimated net unfavorable impact of approximately $500 million, or 4%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.

Emerging markets revenues decreased $303 million, or 10%, in the second quarter of 2020 to $2.8 billion from $3.1 billion in the second quarter of 2019, reflecting an operational decrease of $95 million, or 3%, and an unfavorable impact from foreign exchange of approximately 7%. The operational decrease in emerging markets was primarily driven by lower revenues for

Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK and Sulperazon, in our Biopharma segment, partially offset primarily by growth from Prevenar 13 and Eliquis in our Biopharma segment and Lipitor and Norvasc in our Upjohn segment.

#### Revenues––First Six Months of 2020 vs. First Six Months of 2019

*The following provides an analysis of the change in worldwide revenues by geographic areas in the first six months of 2020:*

| (MILLIONS OF DOLLARS) Operational growth/(decline): | Six Months Ended June 28, 2020 Worldwide | U.S. | International |
| --- | ---: | ---: | ---: |
| Continued growth from certain key brands(a) | $812 | $494 | $318 |
| Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU | 353 | 268 | 85 |
| Higher revenues for the Hospital business in the U.S., primarily driven by increased demand for certain sterile injectable products utilized in the intubation and ongoing treatment of mechanically-ventilated COVID-19 patients as well as continued growth from Panzyga following its November 2018 U.S. launch | 212 | 207 | 6 |
| Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC | 191 | 155 | 35 |
| Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit, new product launches and steady volume and share growth in the U.S. for Inflectra, across hospital channels, clinics and alternate sites of care | 190 | 149 | 41 |
| Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019 | 106 | 106 | — |
| Lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK. As a result, for the first six months of 2019, revenues reflect six months of Consumer Healthcare segment operations, while for the first six months of 2020, there is no contribution from the Consumer Healthcare business | (1,721) | (864) | (857) |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019 | (1,655) | (1,592) | (63) |
| Declines in revenues for Lipitor and Norvasc, primarily resulting from the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion | (254) | 12 | (266) |
| Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Brazil and Japan, all of which is expected to continue | (159) | — | (159) |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition | (58) | (55) | (2) |
| Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China | (47) | (215) | 169 |
| Other operational factors, net | (113) | (121) | 8 |
| Operational growth/(decline), net | (2,141) | (1,457) | (684) |
| Unfavorable impact of foreign exchange | (411) | — | (411) |
| Revenues decrease | $(2,552) | $(1,457) | $(1,096) |

62

(a) Certain key brands represent Ibrance, Eliquis and Xeljanz. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Revenues for the first six months of 2020 included an estimated net unfavorable impact of approximately $350 million, or 1%, due to COVID-19, primarily reflecting unfavorable disruptions to wellness visits for pediatric and adult patients in the U.S. and lower demand for certain products in China, partially offset by increased U.S. demand for certain sterile injectable products as well as increased adult demand for Prevenar 13 in certain international markets.

Emerging markets revenues decreased $624 million, or 10%, in the first six months of 2020 to $5.8 billion from $6.4 billion in the first six months of 2019, reflecting an operational decrease of $328 million, or 5%. Foreign exchange had an unfavorable impact of approximately 5% on emerging markets revenues. The operational decrease in emerging markets was primarily driven by lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK, Lipitor and Norvasc in our Upjohn segment and Sulperazon in our Biopharma segment, partially offset by growth from Prevenar 13, Eliquis, certain anti-infective products, primarily Zavicefta and Zithromax, Ibrance and Xalkori in our Biopharma segment.

### Revenue Deductions

Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends.

*The following table provides information about revenue deductions:*

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | Six Months Ended June 28, 2020 | June 30, 2019 |
| --- | ---: | ---: | ---: | ---: |
| Medicare rebates(a) | $164 | $351 | $359 | $785 |
| Medicaid and related state program rebates(a) | 317 | 459 | 634 | 1,028 |
| Performance-based contract rebates(a), (b) | 972 | 972 | 1,882 | 1,861 |
| Chargebacks(c) | 1,368 | 1,368 | 2,787 | 2,924 |
| Sales allowances(d) | 1,236 | 1,454 | 2,666 | 2,814 |
| Sales returns and cash discounts | 271 | 477 | 542 | 804 |
| Total(e) | $4,329 | $5,082 | $8,871 | $10,216 |

(a) Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.

(b) Performance-based contract rebates include contract rebates with MCOs within the U.S., including health maintenance organizations and PBMs, who receive rebates based on the achievement of contracted performance terms and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contracted performance for specific products or sales milestones.

(c) Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.

(d) Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.

(e) For the three months ended June 28, 2020, associated with the following segments: Biopharma ($3.2 billion) and Upjohn ($1.1 billion). For the three months ended June 30, 2019, associated with the following segments: Biopharma ($3.0 billion), Upjohn ($1.9 billion) and Other ($0.2 billion). For the six months ended June 28, 2020, associated with the following segments: Biopharma ($6.6 billion) and Upjohn ($2.3 billion). For the six months ended June 30, 2019, associated with the following segments: Biopharma ($5.7 billion), Upjohn ($4.2 billion) and Other ($0.3 billion).

Total revenue deductions for the second quarter of 2020 decreased 15%, compared to the second quarter of 2019, and total revenue deductions for the first six months of 2020 decreased 13%, compared to the first six months of 2019, primarily as a result of:

- a decrease in Medicaid and Medicare rebates, driven by a significant decrease in Lyrica sales in the U.S. due to multi-source generic competition that began in July 2019; and
- a decrease in sales returns and cash discounts, primarily due to the non-recurrence of a sales return reserve recorded for Lyrica in the prior year in advance of anticipated multi-source generic competition that began in the U.S. in July 2019.

For information on our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts, including the balance sheet classification of these accruals, see Notes to Condensed Consolidated Financial Statements––*Note 1C. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable.*

### Revenues––Selected Product Discussion

The tables below provide worldwide revenues and revenues by geography, for selected products. References to total change pertain to period-over-period growth rates that include foreign exchange. The difference between the total change and operational change represents the impact of foreign exchange. Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts. An asterisk (\*) indicates the calculation is not meaningful or results are equal to or greater than 100%.

- **Ibrance** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $927 | $831 | 11 |  | $1,779 | $1,572 | 13 |  |
| International | 422 | 430 | (2) | 3 | 819 | 822 | — | 4 |
| Worldwide revenues | $1,349 | $1,261 | 7 | 9 | $2,598 | $2,394 | 9 | 10 |

The operational growth in the second quarter and first six months of 2020 in the U.S. was mainly driven by increased cyclin-dependent kinase (CDK) class penetration and Ibrance’s continued CDK market share leadership in metastatic breast cancer. The operational growth in the second quarter and first six months of 2020 internationally reflects the continued strong volume growth in most markets, partially offset by pricing pressures in certain developed Europe markets.

- **Eliquis alliance revenues and direct sales** (Biopharma): Eliquis has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plus a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant market; the agents in this class were developed as alternative treatment options to warfarin in appropriate patients.

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $722 | $626 | 15 |  | $1,527 | $1,227 | 24 |  |
| International | 550 | 459 | 20 | 25 | 1,045 | 869 | 20 | 24 |
| Worldwide revenues | $1,272 | $1,085 | 17 | 19 | $2,572 | $2,096 | 23 | 24 |

The worldwide operational growth in the second quarter and first six months of 2020 was primarily driven by higher demand due to continued adoption in non-valvular atrial fibrillation as well as oral anti-coagulant market share gains, partially offset by a lower net price. In the second quarter of 2020, U.S. growth was also unfavorably impacted by a lower net price and COVID-19-related wholesaler buying patterns.

- **Prevnar 13/Prevenar 13** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $481 | $612 | (22) |  | $1,275 | $1,490 | (14) |  |
| International | 636 | 567 | 12 | 18 | 1,291 | 1,175 | 10 | 14 |
| Worldwide revenues | $1,116 | $1,179 | (5) | (2) | $2,566 | $2,665 | (4) | (2) |

The decline in the second quarter and first six months of 2020 in the U.S. primarily reflects the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period.

The operational growth in the second quarter and first six months of 2020 internationally primarily reflects significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China.

On June 26, 2019, the ACIP voted to revise the pneumococcal vaccination guidelines and recommend Prevnar 13 for adults 65 and older based on the shared clinical decision making of the provider and patient, which means the decision to vaccinate should be made at the individual level between health care providers and their patients, maintaining reimbursement. The recommendation reaffirms that there remains vaccine preventable pneumococcal disease in the population of adults 65 years or older, which may be prevented through direct vaccination. The ACIP’s recommendation was approved by the directors at the CDC and U.S. Department of Health and Human Services, and published by the CDC in the Morbidity and Mortality Weekly Report in the fourth quarter of 2019. The ACIP’s latest recommendation did not have an impact on Prevnar 13 revenues in 2019, due to timing of the Morbidity and Mortality Weekly Report publication, nor was there impact in the first half of 2020. We expect Prevnar 13 revenues from the adult indication to decline through the remainder of the year.

- **Xeljanz** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $458 | $458 | — |  | $744 | $756 | (2) |  |
| International | 177 | 155 | 14 | 20 | 343 | 279 | 23 | 28 |
| Worldwide revenues | $635 | $613 | 4 | 5 | $1,086 | $1,036 | 5 | 6 |

U.S. revenue was flat in the second quarter of 2020 and declined in the first six months of 2020 primarily due to a lower net price due to higher rebating from commercial contracts signed in 2019. These declines were offset by continued strong demand across all approved indications.

The operational growth internationally in the second quarter and first six months of 2020 was mainly driven by continued uptake in the RA indication and, to a lesser extent, from the recent launch of the UC indication in certain developed markets.

- **Lipitor** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $43 | $30 | 44 |  | $67 | $51 | 33 |  |
| International | 388 | 377 | 3 | 7 | 768 | 979 | (21) | (19) |
| Worldwide revenues | $431 | $407 | 6 | 10 | $836 | $1,029 | (19) | (16) |

The worldwide operational growth in the second quarter primarily reflects significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion. The worldwide operational decline in the first six months of 2020 primarily resulted from the VBP program mentioned above.

- **Lyrica** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $51 | $835 | (94) |  | $132 | $1,724 | (92) |  |
| International | 298 | 340 | (13) | (12) | 574 | 638 | (10) | (10) |
| Worldwide revenues | $349 | $1,175 | (70) | (70) | $706 | $2,362 | (70) | (70) |

The worldwide decline in the second quarter and first six months of 2020 was primarily driven by the U.S. due to the expected significantly lower volumes driven by multi-source generic competition that began in the U.S. in July 2019.

- **Enbrel** (Biopharma, outside the U.S. and Canada):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $— | $— | — |  | $— | $— | — |  |
| International | 337 | 420 | (20) | (16) | 684 | 871 | (21) | (18) |
| Worldwide revenues | $337 | $420 | (20) | (16) | $684 | $871 | (21) | (18) |

65

The worldwide operational decline in the second quarter and first six months of 2020 was primarily due to continued biosimilar competition in most developed Europe markets as well as in Brazil and Japan, all of which is expected to continue.

- **Vyndaqel/Vyndamax** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | --- | --- | ---: | ---: | --- | --- |
| U.S. | $145 | $8 | \* |  | $272 | $8 | \* |  |
| International | 131 | 55 | \* | \* | 236 | 96 | \* | \* |
| Worldwide revenues | $277 | $63 | \* | \* | $508 | $104 | \* | \* |

The growth in the U.S. in the second quarter and first six months of 2020 was driven by the launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for the treatment of ATTR-CM. The operational growth in international markets in the second quarter and first six months of 2020 was primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU.

- **Chantix/Champix** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $179 | $227 | (21) |  | $390 | $439 | (11) |  |
| International | 56 | 49 | 15 | 20 | 115 | 110 | 5 | 8 |
| Worldwide revenues | $235 | $276 | (15) | (14) | $505 | $549 | (8) | (7) |

The worldwide operational revenue decline in the second quarter and first six months of 2020 was driven by the U.S. and primarily reflects expected lower demand resulting from reduced doctor visits, including wellness visits when Chantix is typically prescribed, due to COVID-19-related mobility restrictions or limitations. The decline was partially offset by increased demand in Spain as a result of government reimbursement starting in January 2020.

- **Xtandi alliance revenues** (Biopharma): Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales of Xtandi. Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S. market. Pfizer and Astellas also share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international Xtandi net sales (recorded in *Other (income)/deductions—net).*

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $266 | $201 | 32 |  | $475 | $369 | 29 |  |
| International | — | — | — | — | — | — | — | — |
| Worldwide revenues | $266 | $201 | 32 | 32 | $475 | $369 | 29 | 29 |

The growth in the U.S. in the second quarter and first six months of 2020 was primarily driven by continued strong demand for Xtandi in the metastatic (mCRPC) and non-metastatic (nmCRPC) castration-resistant prostate cancer indications, as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019.

- **Norvasc** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $7 | $11 | (32) |  | $16 | $21 | (23) |  |
| International | 215 | 205 | 5 | 9 | 403 | 495 | (19) | (16) |
| Worldwide revenues | $222 | $216 | 3 | 7 | $419 | $516 | (19) | (16) |

The worldwide operational growth in the second quarter of 2020 reflects significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion. The worldwide operational decline in the first six months of 2020 primarily resulted from the VBP program mentioned above.

- **Sutent** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $61 | $82 | (26) |  | $113 | $153 | (26) |  |
| International | 148 | 166 | (11) | (6) | 301 | 327 | (8) | (4) |
| Worldwide revenues | $209 | $248 | (16) | (13) | $414 | $480 | (14) | (11) |

The worldwide operational decline in the second quarter and first six months of 2020 reflects continued erosion as a result of increased competition in the U.S. and key international developed markets, partially offset by growth in certain emerging markets.

- **Inlyta** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | --- | ---: |
| U.S. | $132 | $60 | \* |  | $248 | $93 | \* |  |
| International | 63 | 44 | 43 | 48 | 116 | 84 | 38 | 42 |
| Worldwide revenues | $195 | $104 | 87 | 89 | $364 | $177 | \* | \* |

The worldwide operational growth in the second quarter and first six months of 2020 was primarily due to increased demand in the U.S. from the FDA approvals in the second quarter of 2019 for combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC.

- **Inflectra/Remsima** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $72 | $74 | (3) |  | $156 | $132 | 18 |  |
| International | 78 | 78 | — | 5 | 153 | 159 | (4) | (1) |
| Worldwide revenues | $150 | $153 | (2) | 1 | $308 | $291 | 6 | 8 |

The worldwide operational revenue growth in the second quarter and first six months of 2020 was primarily driven by switch-to-biosimilar products policies implemented in Canada and steady volume and share growth in the U.S. across hospital channels, clinics and alternate sites of care, partially offset by pricing pressures globally as well as competitive pressures internationally.

While Inflectra has achieved parity access to Remicade® (infliximab) in Medicare Part B, in the U.S., nearly half of all commercial patients are not able to access Inflectra due to exclusionary conduct by J&J. In September 2017, Pfizer filed suit in the U.S. District Court for the Eastern District of Pennsylvania against J&J alleging that J&J’s exclusionary contracts and other anticompetitive practices concerning Remicade violate federal antitrust laws. In June 2019, Pfizer received a Civil Investigative Demand from the Federal Trade Commission (FTC) seeking documents and information relating to the alleged conduct and market conditions at issue in Pfizer’s lawsuit against J&J. Pfizer understands that the FTC’s investigation is focused on J&J’s alleged conduct at issue in Pfizer’s lawsuit against J&J.

- The **Premarin** family of products (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $142 | $182 | (22) |  | $283 | $340 | (17) |  |
| International | 10 | 11 | (7) | 1 | 20 | 21 | (3) | 1 |
| Worldwide revenues | $152 | $193 | (21) | (21) | $304 | $361 | (16) | (16) |

67

The worldwide operational decline in the second quarter and first six months of 2020 was primarily driven by continued competitive pressures in the U.S., which is expected to continue.

- **Celebrex** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $10 | $16 | (33) |  | $22 | $30 | (28) |  |
| International | 129 | 158 | (18) | (17) | 274 | 317 | (14) | (13) |
| Worldwide revenues | $139 | $174 | (20) | (18) | $295 | $347 | (15) | (14) |

The worldwide operational decline in the second quarter and first six months of 2020 was primarily driven by lower volume in certain developed markets, primarily in Japan, in anticipation of generic competition that began in June 2020, Pfizer’s third quarter for international subsidiaries, following patent expiration in November 2019, partially offset by higher volumes in China. The first six months of 2020 were also impacted by pricing pressures and lower volumes in certain other emerging markets.

- **Sulperazon** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $— | $— | — |  | $— | $— | — |  |
| International | 102 | 165 | (38) | (36) | 289 | 342 | (16) | (13) |
| Worldwide revenues | $102 | $165 | (38) | (36) | $289 | $342 | (16) | (13) |

The international operational decline in the second quarter and first six months of 2020 was primarily driven by lower demand in China due to lower infection rates driven by fewer elective surgical procedures, shorter in-patient hospital stays and improved infection control compared to the prior year period.

- **Xalkori** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $37 | $41 | (8) |  | $77 | $75 | 2 |  |
| International | 100 | 92 | 9 | 14 | 210 | 180 | 17 | 21 |
| Worldwide revenues | $138 | $133 | 4 | 7 | $287 | $255 | 12 | 15 |

The worldwide operational growth in the second quarter and first six months of 2020 primarily resulted from growth in China, following the impact of inclusion of Xalkori in the 2019 National Reimbursement Drug List.

- **Viagra** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $11 | $13 | (15) |  | $28 | $52 | (46) |  |
| International | 83 | 102 | (18) | (15) | 193 | 207 | (6) | (4) |
| Worldwide revenues | $94 | $114 | (18) | (15) | $222 | $259 | (15) | (13) |

The worldwide operational decline in the second quarter and first six months of 2020 was primarily driven by emerging markets, primarily China, resulting from mobility restrictions due to COVID-19. The worldwide operational decline in the first six months of 2020 was also impacted by continued volume erosion due to multi-source generic competition in the U.S.

- **Alliance revenues** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. | Six Months Ended June 28, 2020 | June 30, 2019 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $996 | $835 | 19 |  | $2,018 | $1,610 | 25 |  |
| International | 408 | 352 | 16 | 19 | 769 | 666 | 15 | 18 |
| Worldwide revenues | $1,404 | $1,187 | 18 | 19 | $2,786 | $2,277 | 22 | 23 |

The worldwide operational growth in the second quarter and first six months of 2020 was primarily due to increases in Eliquis and Xtandi alliance revenues included in the above discussion.

See Notes to Condensed Consolidated Financial Statements––*Note 14C. Segment, Geographic and Other Revenue Information: Other Revenue Information* for additional information regarding the primary indications or class of the selected products discussed above.

See Notes to Condensed Consolidated Financial Statements—*Note 13. Contingencies and Certain Commitments* for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above.

See the “Patents and Other Intellectual Property Rights” section in Part I, Item 1, “Business” of our 2019 Form 10-K for information regarding the expiration of various patent rights.

### Product Developments—Biopharmaceutical

We continue to invest in R&D to provide potential future sources of revenues through the development of new products, as well as through additional uses for in-line and alliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.

We continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable pipeline that will deliver value in the near term and over time.

For additional information about our R&D organization, see the “Research and Development” section in Part I, Item 1, “Business” of our 2019 Form 10-K.

A comprehensive update of Pfizer’s development pipeline was published as of July 28, 2020 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.

The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well as additional indications and new drug candidates in late-stage development.

*RECENT FDA APPROVALS*

|  |  |  |
| --- | --- | --- |
| **PRODUCT** | **INDICATION** | **DATE APPROVED** |
| Bavencio (avelumab) | For the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, which is being developed in collaboration with Merck KGaA, Germany | June 2020 |
| Nyvepria (pegfilgrastim-apgf)(a) | A biosimilar to Neulasta® (pegfilgrastim) to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia | June 2020 |
| Braftovi (encorafenib)(b) | Braftovi (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAFV600E-mutant metastatic colorectal cancer after prior therapy | April 2020 |
| Xtandi (enzalutamide) | Treatment of metastatic castration-sensitive prostate cancer, which is being developed through a collaboration with Astellas | December 2019 |
| Abrilada (adalimumab-afzb)(c) | A biosimilar to Humira® (adalimumab) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, UC and plaque psoriasis | November 2019 |

(a) Neulasta® is a registered U.S. trademark of Amgen Inc.

(b) Erbitux® is a registered trademark of ImClone LLC.

(c) Humira® is a registered trademark of AbbVie Biotechnology Ltd. Pfizer is working to make Abrilada available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. Current plans are to launch Abrilada in 2023.

*PENDING U.S. NDAs AND SUPPLEMENTAL FILINGS*

|  |  |  |
| --- | --- | --- |
| **PRODUCT** | **PROPOSED INDICATION** | **DATE FILED\*** |
| tanezumab | For patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics, which is being developed in collaboration with Lilly | March 2020 |

\* The date set forth in this column is the date on which the FDA accepted our submission.

*REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN*

| PRODUCT | DESCRIPTION OF EVENT | DATE APPROVED | DATE FILED\* |
| --- | --- | --- | ---: |
| Bosulif (bosutinib) | Application approved in Japan for the first-line treatment of chronic myelogenous leukemia (CML) | June 2020 | — |
| Daurismo (glasdegib) | Application approved in the EU for Daurismo (glasdegib) in combination with low-dose cytarabine, a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) AML in adult patients who are not candidates for standard chemotherapy | June 2020 | — |
| Bavencio (avelumab) | Application filed in the EU for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma, which is being developed in collaboration with Merck KGaA, Germany | — | June 2020 |
| Braftovi (encorafenib)(a) | Application approved in the EU for Braftovi (encorafenib) in combination with Erbitux® (cetuximab), for the treatment of adult patients with mCRC with a BRAF mutation, who have received prior systemic therapy, which is being developed in collaboration with the Pierre Fabre Group | June 2020 | — |
| Bavencio (avelumab) | Application filed in Japan for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma, which is being developed in collaboration with Merck KGaA, Germany | — | May 2020 |
| Ruxience (rituximab)(b) | Application approved in the EU for a biosimilar to MabThera® (rituximab) for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, RA, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris | April 2020 | — |
| Staquis (crisaborole) | Application approved in the EU for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients from 2 years of age with ≤ 40% body surface area affected | March 2020 | — |
| tanezumab | Application filed in the EU for adult patients with moderate to severe chronic pain associated with OA for whom treatment with NSAIDs and/or an opioid is ineffective, not tolerated or inappropriate | — | March 2020 |
| Braftovi (encorafenib) and Mektovi (binimetinib) | Application filed in Japan for second-or-third-line treatment of BRAF-mutant mCRC in patients who have received prior systemic therapy, which is being developed in collaboration with Ono Pharmaceutical Co., Ltd. | — | March 2020 |
| Vyndaqel (tafamidis free acid) | Application approved in the EU for a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy | February 2020 | — |
| Amsparity (adalimumab)(c) | Application approved in the EU for a biosimilar to Humira® (adalimumab) for the treatment of certain patients with RA, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, UC, uveitis, and pediatric plaque psoriasis | February 2020 | — |
| Xeljanz (tofacitinib) | Application approved in the EU for Xeljanz (tofacitinib) 11 mg prolonged release tablets in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs | December 2019 | — |
| Bavencio (avelumab) | Application approved in Japan for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany | December 2019 | — |
| Bavencio (avelumab) | Application approved in the EU for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany | October 2019 | — |
| PF-06881894(d) | Application filed in the EU for a potential biosimilar to Neulasta® (pegfilgrastim) | — | October 2019 |
| Rituximab Pfizer (rituximab)(e) | Application approved in Japan for a biosimilar to Rituxan® (rituximab) for the treatment of CD20-positive, B-cell non-Hodgkin’s Lymphoma, CD20-positive, B-cell lymphoproliferative disease under immunosuppression, and Granulomatosis with polyangiitis, and microscopic polyangiitis | September 2019 | — |
| Xtandi (enzalutamide) | Application filed in the EU for the treatment of metastatic castration-sensitive prostate cancer, which is being developed through a collaboration with Astellas | — | July 2019 |

\* For applications in the EU, the dates set forth in this column are the dates on which the EMA validated our submissions.

(a) Erbitux® is a registered trademark of ImClone LLC.

(b) MabThera® is a registered trademark of F. Hoffman-La Roche AG.

(c) Humira® is a registered trademark of AbbVie Biotechnology Ltd. Pfizer does not currently plan to commercialize Amsparity in the EU due to unfavorable market conditions.

(d) Neulasta® is a registered trademark of Amgen Inc.

(e) Rituxan® is a registered trademark of Biogen MA Inc.

| LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS |  |
| --- | --- |
| **PRODUCT** | **PROPOSED INDICATION** |
| Bavencio (avelumab) | A monoclonal antibody that inhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung cancer, which is being developed in collaboration with Merck KGaA, Germany |
| Daurismo (glasdegib)(a) | A smoothened inhibitor, in combination with cytarabine and daunorubicin, for the treatment of AML |
| Ibrance (palbociclib) | Treatment of HER2+ advanced breast cancer, in collaboration with the Alliance Foundation Trials, LLC |
| Ibrance (palbociclib) | Treatment of high-risk early breast cancer, in collaboration with the German Breast Group |
| Lorbrena (lorlatinib) | Treatment of patients with metastatic non-small cell lung cancer whose tumors are ALK-positive as detected by an FDA-approved test |
| Xeljanz (tofacitinib) | Treatment of ankylosing spondylitis |
| Xtandi (enzalutamide) | Treatment of non-metastatic castration-sensitive prostate cancer, which is being developed through a collaboration with Astellas |
| Talzenna (talazoparib) | An oral PARP inhibitor, in combination with Xtandi (enzalutamide), for the treatment of metastatic castration-resistant prostate cancer |

(a) In May 2020, we accepted the recommendation of the independent Data Monitoring Committee to stop the Non-Intensive cohort of the Phase 3 clinical trial for BRIGHT AML 1019, as it is unlikely to show a statistically significant improvement in the primary endpoint of overall survival. No important new safety signals were observed in patients treated with glasdegib. A separate cohort of BRIGHT AML 1019 evaluates glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) for the treatment of adult patients with previously untreated AML, and the cohort is ongoing and remains blinded.

In May 2020, we and the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation announced that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee of the collaborative Ibrance (palbociclib) Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival. No unexpected new safety signals were observed in patients receiving Ibrance. When available, the full results from the PALLAS study will be shared with the scientific community.

| NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT |  |
| --- | --- |
| **CANDIDATE** | **PROPOSED INDICATION** |
| abrocitinib (PF-04965842) | A Janus kinase 1 (JAK1) inhibitor for the treatment of moderate-to-severe atopic dermatitis |
| aztreonam-avibactam (PF-06947387) | A beta lactam/beta lactamase inhibitor for the treatment of patients with infections caused by Gram-negative bacteria, including those that produce metallo-beta-lactamases, for which there are limited or no treatment options |
| fidanacogene elaparvovec (PF-06838435) | An investigational gene therapy for the treatment of hemophilia B |
| PF-06482077 | A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae serotypes covered by the vaccine in adults 18 years of age and older |
| PF-06482077 | A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae serotypes covered by the vaccine in infants |
| PF-06425090 | A prophylactic vaccine for prevention of primary clostridioides difficile infection (CDI) in individuals |
| PF-06886992 | Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A,B,C,W and Y in persons one through 25 years of age |
| PF-06928316 | A respiratory syncytial virus vaccine for the prevention of RSV disease in young infants through maternal immunization and in older adults through direct immunization |
| PF-07302048 (BNT162) | A messenger RNA-based vaccine for the prevention of SARS-CoV-2, the virus that causes COVID-19 disease, in partnership with BioNTech |
| PF-07265803 | An oral inhibitor of p38 mitogen-activated protein kinase for the treatment of patients with symptomatic dilated cardiomyopathy due to a Lamin A/C gene mutation |
| ritlecitinib (PF-06651600) | A selective dual Janus kinase 3 (JAK3) and Tyrosine kinase Expressed in hepatocellular Carcinoma (TEC) family inhibitor for the treatment of patients with moderate to severe alopecia areata |
| sasanlimab (PF-06801591) | A monoclonal antibody that inhibits PD-1, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of non-muscle invasive bladder cancer |
| somatrogon (PF-06836922) | A long-acting hGH-CTP for the treatment of growth hormone deficiency in children, which is being developed in collaboration with OPKO |
| somatrogon (PF-06836922) | A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed in collaboration with OPKO |
| tanezumab | An anti-nerve growth factor monoclonal antibody for the treatment of cancer pain, which is being developed in collaboration with Lilly |

Additional product-related programs are in various stages of discovery and development.

### Costs and Expenses

The changes in expenses below reflect, among other things, a decline in expenses resulting from the July 31, 2019 completion of the Consumer Healthcare JV transaction with GSK (see Notes to Condensed Consolidated Financial Statements—*Note 2B. Acquisition, Equity-Method Investment and Licensing Arrangements: Equity-Method Investment*). In addition, the COVID-19 pandemic impacted certain operating expenses in the second quarter and first six months of 2020.

### Cost of Sales

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of sales | $2,281 | $2,576 | (11) | $4,658 | $5,009 | (7) |
| As a percentage of Revenues | 19.3% | 19.4% |  | 19.5% | 19.0% |  |

*Cost of sales* decreased $295 million in the second quarter of 2020 and $351 million in the first six months of 2020, primarily due to:

- the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK; and
- a favorable impact of foreign exchange,

partially offset by:

- the unfavorable impact of incremental costs incurred in response to the COVID-19 pandemic.

The decrease in *Cost of sales* in the first six months of 2020 was also partially offset by the net increase in sales volumes for various products within our product portfolio.

The slight decrease in *Cost of sales* as a percentage of revenues in the second quarter of 2020, compared to the same period in 2019, was primarily due to all of the factors discussed above, as well as a favorable change in product mix, primarily driven by revenue growth in the Oncology portfolio and Vyndaqel, and an increase in alliance revenues, which have no associated cost of sales, partially offset by the impact of the lower Lyrica revenues in developed markets due to U.S. multi-source generic competition that began in July 2019.

The increase in *Cost of sales* as a percentage of revenues in the first six months of 2020, compared to the same period in 2019, was primarily due to all of the factors discussed above, as well as the impact of the lower Lyrica revenues in developed markets due to U.S. multi-source generic competition that began in July 2019, partially offset by a favorable change in product mix, primarily driven by revenue growth in the Oncology portfolio and Vyndaqel, and an increase in alliance revenues, which have no associated cost of sales.

### Selling, Informational and Administrative (SI&A) Expenses

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, informational and administrative expenses | $3,030 | $3,511 | (14) | $5,903 | $6,850 | (14) |
| As a percentage of Revenues | 25.7% | 26.5% |  | 24.8% | 26.0% |  |

SI&A expenses decreased $481 million in the second quarter of 2020, primarily due to:

- the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK;
- lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic;
- a decrease in field force expense as well as advertising and promotion expenses, primarily related to Lipitor and Norvasc, due to the VBP program in China, which was initially implemented in certain cities in March 2019 and expanded nationwide beginning in December 2019, as well as Lyrica in the U.S. due to generic competition that began in July 2019 and anticipated generic competition for Celebrex in Japan beginning in June 2020;
- lower spending associated with corporate enabling functions; and
- the favorable impact of foreign exchange,

partially offset by:

- legal entity restructuring, as well as separation costs associated with our planned Upjohn transaction with Mylan.

SI&A expenses decreased $947 million in the first six months of 2020, mostly due to:

- the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK;
- a reduction in field force expense as well as advertising and promotion expenses, primarily related to Lyrica in the U.S. due to generic competition that began in July 2019 and the anticipated generic competition for Celebrex in Japan that began in June 2020, as well as a decrease in Lipitor and Norvasc expenses due to the VBP program in China, which was initially implemented in certain cities in March 2019 and expanded nationwide beginning in December 2019;
- lower spending associated with corporate enabling functions;
- lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic;
- a reduction to expense resulting from the decrease in our liability to be paid to participants of our supplemental savings plan;
- lower investments across the Inflammation & Immunology portfolio; and
- the favorable impact of foreign exchange,

partially offset by:

- legal entity restructuring, as well as separation costs associated with our planned Upjohn transaction with Mylan.

### Research and Development (R&D) Expenses

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development expenses | $2,132 | $1,842 | 16 | $3,856 | $3,544 | 9 |
| As a percentage of Revenues | 18.1% | 13.9% |  | 16.2% | 13.4% |  |

R&D expenses increased $290 million in the second quarter 2020, primarily due to:

- costs related to our collaboration agreement with BioNTech to co-develop a COVID-19 vaccine, including an upfront payment to BioNTech; and
- an upfront payment to Valneva,

partially offset by:

- a net reduction of spending across our Oncology, Inflammation & Immunology, Rare Disease, Internal Medicine and Vaccines portfolios, as well as delays in program costs related to COVID-19.

R&D expenses increased $311 million in the first six months of 2020, mostly due to:

- costs related to our collaboration agreement with BioNTech to co-develop a COVID-19 vaccine, including an upfront payment to BioNTech;
- an upfront payment to Valneva; and
- increased investments towards building new capabilities and driving automation,

partially offset by:

- a decrease in the value of the portfolio performance share grants reflecting the decrease in the price of Pfizer’s common stock in the first half of 2020; and
- a net reduction of spending across our Oncology, Inflammation & Immunology, Rare Disease, Internal Medicine and Vaccines portfolios, as well as delays in program costs related to COVID-19.

For additional information on Cost of sales, SI&A and R&D expenses by operating segment, see the “Analysis of Operating Segment Information” section of this MD&A.

### Amortization of Intangible Assets

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Amortization of intangible assets | $905 | $1,184 | (24) | $1,790 | $2,367 | (24) |
| As a percentage of Revenues | 7.7% | 8.9% |  | 7.5% | 9.0% |  |

Amortization of intangible assets decreased $279 million in the second quarter of 2020 and $577 million in the first six months of 2020, primarily due to the non-recurrence of amortization expense as a result of fully amortized assets and the impairment of Eucrisa in the fourth quarter of 2019, partially offset by an increase in amortization expense related to intangible assets from our acquisition of Array.

For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 2A. Acquisition, Equity-Method Investment and Licensing Arrangements: Acquisition* and —*Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.*

### Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | --- |
| Restructuring credits—acquisition-related costs(a) | $(1) | $(206) | (100) | $— | $(214) | (100) |
| Restructuring charges—cost reduction initiatives(b) | 341 | 62 | \* | 396 | 81 | \* |
| Restructuring charges/(credits) | 340 | (144) | \* | 396 | (134) | \* |
| Transaction costs(c) | 11 | — | \* | 14 | — | \* |
| Integration costs and other(c) | 11 | 29 | (62) | 21 | 64 | (67) |
| Restructuring charges and certain acquisition-related costs | 362 | (115) | \* | 431 | (69) | \* |
| Net periodic benefit costs | 5 | 4 | 24 | 29 | 10 | \* |
| Total additional depreciation—asset restructuring | 6 | 10 | (36) | 6 | 23 | (71) |
| Total implementation costs | 75 | 42 | 77 | 99 | 69 | 45 |
| Costs associated with acquisitions and cost-reduction/productivity initiatives(d) | $449 | $(59) | \* | $566 | $32 | \* |
| \* Indicates calculation not meaningful or results are equal to or greater than 100%. |  |  |  |  |  |  |

(a) Includes employee termination costs, asset impairments and other exit costs associated with business combinations. Credits for the second quarter and the first six months of 2019 were mostly due to the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple years. See Notes to Consolidated Financial Statements––*Note 5D. Tax Matters: Tax Contingencies* in our 2019 Financial Report.

(b) Includes employee termination costs, asset impairments and other exit costs not associated with acquisitions. The charges for the second quarter and the first six months of 2020 primarily represent employee termination costs associated with our Transforming to a More Focused Company program. For the second quarter of 2019, the charges were composed of employee termination costs and exit costs, partially offset by lower asset write-downs, and for the first six months of 2019 were mostly related to employee termination costs and exit costs.

(c) For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

(d) Comprises *Restructuring charges and certain acquisition-related* costs as well as costs associated with our cost-reduction/productivity initiatives included in *Cost of sales, Research and development expenses, Selling, informational and administrative expenses* and/or *Other (income)/deductions––net* as appropriate. For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

#### Transforming to a More Focused Company Program

With the formation of the GSK Consumer Healthcare joint venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines. As a result, we began, in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base, which is expected to be 20% less (based on the midpoint of the range for 2020 New Pfizer revenue guidance, compared to 2019 Total Company reported revenue) as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions. While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&D, Manufacturing and Commercial.

We expect the costs associated with this multi-year program to be incurred from 2020 through 2022 and to total approximately $1.2 billion on a pre-tax basis, with substantially all of the costs to be cash expenditures. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs. We expect gross cost savings of approximately $900 million to be achieved primarily over the two-year period 2021-2022.

Also as part of this program, in connection with the legacy cost reduction initiatives, primarily related to manufacturing activities, we expect to incur costs of approximately $400 million, with approximately 20% of the costs to be non-cash. The costs associated with this effort are expected to be incurred from 2020 through 2022, and will primarily include implementation costs, product transfer costs, exit costs, as well as accelerated depreciation. We expect targeted net cost savings of approximately $200 million, with approximately 30% realized in the first half of 2020, and the remaining expected to be achieved in the second half of 2020 through 2022.

Savings are expected to be realized primarily in corporate enabling functions and in manufacturing (as described in the Notes to Condensed Consolidated Financial Statements––*Note 14A. Segment, Geographic and Other Revenue Information: Segment Information).*

Certain qualifying costs associated with this program were recorded in the fourth quarter of 2019 and in the first and second quarters of 2020 and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A for additional information.

For additional information about this program and expected and actual total costs, see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

In addition to this major program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.

### Other (Income)/Deductions—Net

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Other (income)/deductions––net | $(862) | $126 | \* | $(641) | $218 | \* |
| \* Indicates calculation not meaningful or results are equal to or greater than 100%. |  |  |  |  |  |  |

For information about the components of *Other (income)/deductions—net*, see Notes to Condensed Consolidated Financial Statements—*Note 4. Other (Income)/Deductions—Net.*

See also the “Analysis of Operating Segment Information” section of this MD&A.

### Provision/(Benefit) for Taxes on Income

| (MILLIONS OF DOLLARS) | Three Months Ended June 28, 2020 | June 30, 2019 | % Change | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Provision/(benefit) for taxes on income | $519 | $(915) | \* | $993 | $(481) | \* |
| Effective tax rate on continuing operations | 13.1% | (22.1)% |  | 12.7% | (5.7)% |  |
| \* Indicates calculation not meaningful or results are equal to or greater than 100%. |  |  |  |  |  |  |

For information about our effective tax rate and the events and circumstances contributing to the changes between periods, see Notes to Condensed Consolidated Financial Statements—*Note 5. Tax Matters.*

### Non-GAAP Financial Measure (Adjusted Income)

### General Description of Non-GAAP Financial Measure (Adjusted Income)

Adjusted income is an alternative view of performance used by management. We measure the performance of the overall Company on this basis in conjunction with other performance metrics. Because Adjusted income is an important internal measurement for Pfizer, we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted income, certain components of Adjusted income, and Adjusted diluted earnings per share in order to portray the results of our major operations––the discovery, development, manufacture, marketing and sale of prescription medicines and vaccines––prior to considering certain income statement elements. We have defined Adjusted income as *Net income attributable to Pfizer Inc.* before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Also, see the “Non-GAAP Financial Measure (Adjusted Income)––General Description of Non-GAAP Financial Measure (Adjusted Income)” section of our 2019 Financial Report for additional information. Similarly, we have defined the Adjusted income components as *Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets* and *Other (income)/deductions––net* each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. We have defined Adjusted diluted earnings per share as *Earnings per common share attributable to Pfizer Inc.––diluted* before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items. The Adjusted income measure, the Adjusted income component measures and the Adjusted diluted earnings per share measure are not, and should not be viewed as, substitutes for U.S. GAAP net income, U.S. GAAP net income components or U.S. GAAP diluted earnings per share.

The following are examples of how the Adjusted income and Adjusted diluted earnings per share measures are utilized:

- senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income and Adjusted diluted earnings per share basis;
- our annual budgets are prepared on an Adjusted income and Adjusted diluted earnings per share basis; and
- senior management’s annual compensation is derived, in part, using Adjusted income and Adjusted diluted earnings per share measures.

Effective in 2020, the bonus plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part by three metrics, one of which is Adjusted diluted earnings per share, which is derived from Adjusted income and accounts for 40% of the bonus pool funding. Additionally, the payout for some Performance Share Awards is determined in part by Adjusted net income, which is derived from Adjusted income.

Adjusted income and its components and Adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, Adjusted income and its components (unlike U.S. GAAP net income and its components) and Adjusted diluted earnings per share (unlike U.S. GAAP diluted earnings per share) may not be comparable to the calculation of similar measures of other companies. Adjusted income and its components and Adjusted diluted earnings per share are presented solely to permit investors to more fully understand how management assesses performance.

We also recognize that, as internal measures of performance, the Adjusted income and its components and Adjusted diluted earnings per share measures have limitations, and we do not restrict our performance-management process solely to these metrics. A limitation of these measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and they do not provide a comparable view of our performance relative to other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly-traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer’s long-term incentive compensation plans.

See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the second quarter and first six months of 2020 and 2019 below.

### Purchase Accounting Adjustments

Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts, primarily associated with Wyeth (acquired in 2009), Hospira (acquired in 2015), Anacor (acquired in 2016), Medivation (acquired in 2016) and Array (acquired in 2019), can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets (primarily manufacturing facilities), amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.

### Acquisition-Related Costs

Adjusted income is calculated prior to considering transaction, integration, restructuring charges and additional depreciation costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.

### Discontinued Operations

Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such operations.

### Certain Significant Items

Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive and/or unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspects of their nature. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, major non-acquisition-related cost-reduction programs stand on their own as they are specific to an event or goal with a defined term, but we may have subsequent programs based on reorganizations of the business, cost productivity or in response to loss of exclusivity or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Unusual items may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be: (i) gains on the completion of joint venture transactions such as the gain on the completion of the GSK Consumer Healthcare joint venture transaction discussed in Notes to Condensed Consolidated Financial Statements—*Note 2B. Acquisition, Equity-Method Investment and Licensing Arrangements: Equity-Method Investment*, (ii) gains and losses from equity securities because of their inherent volatility, which we do not control and cannot predict with any level of certainty and because we do not believe that including these gains and losses assists investors in understanding our business or is reflective of our core operations and business; (iii) a major non-acquisition-related restructuring charge and associated implementation costs; (iv) amounts related to certain disposals of businesses, products or facilities that do not qualify as discontinued operations under U.S. GAAP; (v) certain intangible asset impairments; (vi) adjustments related to the resolution of certain tax positions; (vii) the impact of adopting certain significant, event-driven tax legislation, such as the TCJA discussed in Notes to Consolidated Financial Statements—*Note 5A. Tax Matters: Taxes on Income from Continuing Operations* in Pfizer’s 2019 Financial Report; or (viii) charges related to certain legal matters, such as certain of those discussed in Notes to Condensed Consolidated Financial Statements—*Note 13A. Contingencies and Certain Commitments: Legal Proceedings,* included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be considered certain significant items.

### Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Three Months Ended June 28, 2020 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$11,801** | $— | $— | $— | $— | $11,801 |
| Cost of sales | **2,281** | 5 | — | — | (49) | 2,236 |
| Selling, informational and administrative expenses | **3,030** | (1) | — | — | (221) | 2,808 |
| Research and development expenses | **2,132** | 1 | — | — | (238) | 1,895 |
| Amortization of intangible assets | **905** | (834) | — | — | — | 71 |
| Restructuring charges and certain acquisition-related costs | **362** | — | (21) | — | (341) | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **—** | — | — | — | — | — |
| Other (income)/deductions––net | **(862)** | (82) | — | — | 582 | (361) |
| Income from continuing operations before provision/(benefit) for taxes on income | **3,953** | 910 | 21 | — | 268 | 5,152 |
| Provision/(benefit) for taxes on income(b) | **519** | 187 | 5 | — | 30 | 741 |
| Income from continuing operations | **3,434** | 723 | 16 | — | 238 | 4,411 |
| Discontinued operations––net of tax | **—** | — | — | — | — | — |
| Net income attributable to noncontrolling interests | **8** | — | — | — | — | 8 |
| Net income attributable to Pfizer Inc. | **3,426** | 723 | 16 | — | 238 | 4,403 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **0.61** | 0.13 | — | — | 0.04 | 0.78 |

See end of tables for note (a) and (b).

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Six Months Ended June 28, 2020 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$23,829** | $— | $— | $— | $— | $23,829 |
| Cost of sales | **4,658** | 9 | — | — | (81) | 4,586 |
| Selling, informational and administrative expenses | **5,903** | — | — | — | (351) | 5,553 |
| Research and development expenses | **3,856** | 3 | — | — | (236) | 3,622 |
| Amortization of intangible assets | **1,790** | (1,648) | — | — | — | 142 |
| Restructuring charges and certain acquisition-related costs | **431** | — | (35) | — | (396) | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **(6)** | — | — | — | 6 | — |
| Other (income)/deductions––net | **(641)** | (85) | — | — | 179 | (547) |
| Income from continuing operations before provision/(benefit) for taxes on income | **7,838** | 1,722 | 34 | — | 879 | 10,474 |
| Provision/(benefit) for taxes on income(b) | **993** | 367 | 8 | — | 170 | 1,539 |
| Income from continuing operations | **6,845** | 1,355 | 26 | — | 709 | 8,934 |
| Discontinued operations––net of tax | **—** | — | — | — | — | — |
| Net income attributable to noncontrolling interests | **17** | — | — | — | — | 17 |
| Net income attributable to Pfizer Inc. | **6,828** | 1,355 | 26 | — | 709 | 8,917 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **1.22** | 0.24 | — | — | 0.13 | 1.59 |

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Three Months Ended June 30, 2019 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$13,264** | $— | $— | $— | $— | $13,264 |
| Cost of sales | **2,576** | 6 | — | — | (26) | 2,556 |
| Selling, informational and administrative expenses | **3,511** | 1 | (1) | — | (47) | 3,464 |
| Research and development expenses | **1,842** | 1 | — | — | (18) | 1,825 |
| Amortization of intangible assets | **1,184** | (1,117) | — | — | — | 67 |
| Restructuring charges and certain acquisition-related costs | **(115)** | — | 177 | — | (62) | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **—** | — | — | — | — | — |
| Other (income)/deductions––net | **126** | (70) | — | — | (156) | (100) |
| Income from continuing operations before provision/(benefit) for taxes on income | **4,141** | 1,178 | (176) | — | 309 | 5,452 |
| Provision/(benefit) for taxes on income(b) | **(915)** | 222 | 6 | — | 1,610 | 923 |
| Income from continuing operations | **5,056** | 957 | (182) | — | (1,301) | 4,529 |
| Discontinued operations––net of tax | **—** | — | — | — | — | — |
| Net income attributable to noncontrolling interests | **10** | — | — | — | — | 10 |
| Net income attributable to Pfizer Inc. | **5,046** | 957 | (182) | — | (1,301) | 4,520 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **0.89** | 0.17 | (0.03) | — | (0.23) | 0.80 |

78

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Six Months Ended June 30, 2019 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$26,382** | $— | $— | $— | $— | $26,382 |
| Cost of sales | **5,009** | 10 | — | — | (48) | 4,971 |
| Selling, informational and administrative expenses | **6,850** | 1 | (2) | — | (74) | 6,775 |
| Research and development expenses | **3,544** | 3 | — | — | (29) | 3,518 |
| Amortization of intangible assets | **2,367** | (2,237) | — | — | — | 130 |
| Restructuring charges and certain acquisition-related costs | **(69)** | — | 150 | — | (81) | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **—** | — | — | — | — | — |
| Other (income)/deductions––net | **218** | 6 | — | — | (459) | (235) |
| Income from continuing operations before provision/(benefit) for taxes on income | **8,463** | 2,217 | (148) | — | 691 | 11,223 |
| Provision/(benefit) for taxes on income(b) | **(481)** | 446 | 11 | — | 1,822 | 1,797 |
| Income from continuing operations | **8,945** | 1,771 | (159) | — | (1,131) | 9,426 |
| Discontinued operations––net of tax | **—** | — | — | — | — | — |
| Net income attributable to noncontrolling interests | **15** | — | — | — | — | 15 |
| Net income attributable to Pfizer Inc. | **8,929** | 1,771 | (159) | — | (1,131) | 9,410 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **1.56** | 0.31 | (0.03) | — | (0.20) | 1.65 |

(a) For details of adjustments, see “Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income” below.

(b) The effective tax rate on Non-GAAP Adjusted income was 14.4% in the second quarter of 2020, compared to 16.9% in the second quarter of 2019. The effective tax rate on Non-GAAP Adjusted income was 14.7% in the first six months of 2020, compared to 16.0% in the first six months of 2019. The decreases were primarily due to a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.

#### Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income

| (MILLIONS OF DOLLARS) Purchase accounting adjustments | Three Months Ended June 28, 2020 | June 30, 2019 | Six Months Ended June 28, 2020 | June 30, 2019 |
| --- | ---: | ---: | ---: | ---: |
| Amortization, depreciation and other(a) | $915 | $1,185 | $1,731 | $2,227 |
| Cost of sales | (5) | (6) | (9) | (10) |
| Total purchase accounting adjustments––pre-tax | 910 | 1,178 | 1,722 | 2,217 |
| Income taxes(b) | (187) | (222) | (367) | (446) |
| Total purchase accounting adjustments––net of tax | 723 | 957 | 1,355 | 1,771 |
| Acquisition-related costs |  |  |  |  |
| Restructuring credits(c) | (1) | (206) | — | (214) |
| Transaction costs(c) | 11 | — | 14 | — |
| Integration costs and other(c) | 11 | 29 | 21 | 64 |
| Additional depreciation––asset restructuring(d) | — | 1 | — | 2 |
| Total acquisition-related costs––pre-tax | 21 | (176) | 34 | (148) |
| Income taxes(e) | (5) | (6) | (8) | (11) |
| Total acquisition-related costs––net of tax | 16 | (182) | 26 | (159) |
| Discontinued operations |  |  |  |  |
| Total discontinued operations––net of tax, attributable to Pfizer Inc.(f) | — | — | — | — |
| Certain significant items |  |  |  |  |
| Restructuring charges––cost reduction initiatives(g) | 341 | 62 | 396 | 81 |
| Implementation costs and additional depreciation––asset restructuring(h) | 82 | 51 | 106 | 89 |
| Net gains recognized during the period on equity securities(i) | (696) | (25) | (501) | (136) |
| Certain legal matters, net(i) | 17 | 15 | 26 | 9 |
| Certain asset impairments(i) | — | 10 | — | 149 |
| Business and legal entity alignment costs(j) | 174 | 141 | 289 | 264 |
| Net losses on early retirement of debt(i) | — | — | — | 138 |
| Other(k) | 350 | 56 | 563 | 97 |
| Total certain significant items––pre-tax | 268 | 309 | 879 | 691 |
| Income taxes(l) | (30) | (1,610) | (170) | (1,822) |
| Total certain significant items––net of tax | 238 | (1,301) | 709 | (1,131) |
| Total purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items––net of tax, attributable to Pfizer Inc. | $977 | $(526) | $2,090 | $481 |

(a) Included primarily in *Amortization of intangible assets.*

(b) Included in *Provision /(benefit) for taxes on income.* Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate.

(c) Included in *Restructuring charges and certain acquisition-related costs.* For additional information, see the “Costs and Expenses—Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

(d) Included in *Selling, informational and administrative expenses* for the three and six months ended June 30, 2019. Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions.

(e) Included in *Provision/(benefit) for taxes on income.* Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. The second quarter and first six months of 2019 include the impact of the non-taxable reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years.

(f) Included in *Discontinued operations––net of tax.*

(g) Amounts relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in *Restructuring charges and certain acquisition-related costs* (see the “Costs and Expenses—Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives).*

(h) Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives*). For the three months ended June 28, 2020, primarily included in *Cost of sales (*$16 million) and *Selling, informational and administrative expenses (*$63 million). For the six months ended June 28, 2020, primarily included in *Cost of sales (*$31 million) and *Selling, informational and administrative expenses (*$78 million). For the three months ended June 30, 2019, included in *Cost of sales (*$24 million), *Selling, informational and administrative expenses (*$16 million) and *Research and development expenses (*$11 million). For the six months ended June 30, 2019, included in *Cost of sales (*$46 million), *Selling, informational and administrative expenses (*$25 million) and *Research and development expenses (*$18 million).

(i) Included in *Other (income)/deductions—net* (see Notes to Condensed Consolidated Financial Statements—*Note 4. Other (Income)/Deductions—Net).*

(j) For the three months ended June 28, 2020, primarily included in *Cost of sales (*$30 million) and *Selling, informational and administrative expenses (*$138 million), and for the six months ended June 28, 2020, primarily included in *Cost of sales (*$45 million) and *Selling, informational and administrative* *expenses (*$235 million) and primarily represents legal entity restructuring, as well as separation costs associated with our planned Upjohn transaction with Mylan, and mainly includes consulting, legal, tax and advisory services. For the three and six months ended June 30, 2019, primarily included in *Other (income)/deductions––net* and represented incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily included consulting, legal, tax and advisory services.

(k) For the three months ended June 28, 2020, primarily included in *Selling, informational and administrative expenses (*$21 million), *Research and development expenses (*$229 million) and *Other (income)/deductions––net (*$97 million). For the first six months of 2020, primarily included in *Selling, informational and administrative expenses (*$37 million)*, Research and development expenses (*$230 million) and *Other (income)/deductions––net (*$296 million). For the three months ended June 30, 2019, primarily included in *Selling, informational and administrative expenses (*$28 million) and *Other (income)/deductions––net (*$19 million). For the first six months of 2019, primarily included in *Selling, informational and administrative expenses (*$41 million), *Research and development expenses (*$11 million) and *Other (income)/deductions––net (*$43 million). Among other things, the second quarter of 2020 includes charges of $85 million and the first six months of 2020 includes charges of $245 million recorded in *Other (income)/deductions––net,* primarily representing our pro rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture. The second quarter and first six months of 2020 also include upfront payments of $130 million to Valneva SE and $72 million to BioNTech SE, which were recorded to *Research and development expenses.*

(l) Included in *Provision/(benefit) for taxes on income*. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. The second quarter and first six months of 2019 were favorably impacted primarily by a benefit recorded of approximately $1.4 billion, representing tax and interest, resulting from the favorable settlement of an IRS audit for multiple tax years, as well as the tax benefit recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA.

### Analysis of Operating Segment Information

The following tables and associated notes provide additional information about the performance of each of our two reportable operating segments—Biopharma and Upjohn, and our Consumer Healthcare operating segment through July 31, 2019. For additional information about each operating segment, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook—Our Strategy—Organizing for Growth” section of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 14. Segment, Geographic and Other Revenue Information.*

Acquisitions and other business development activities completed in 2019 and in the first half of 2020, including the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture, impacted financial results in the periods presented. For additional information, see Notes to Consolidated Financial Statements—*Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation* in our 2019 Financial Report, and Notes to Condensed Consolidated Financial Statements—*Note 2. Acquisition, Equity-Method Investment and Licensing Arrangements.*

*The following tables provide revenue and cost information by reportable operating segment and a reconciliation of that information to our condensed consolidated statements of income:*

| (MILLIONS OF DOLLARS) | Second Quarter of 2020 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $9,795 | $2,006 | $— | $11,801 | $— | **$11,801** |
| Cost of sales | 1,713 | 506 | 17 | 2,236 | 44 | **2,281** |
| % of revenue | 17.5% | 25.2% | \* | 18.9% | \* | **19.3%** |
| Selling, informational and administrative expenses | 1,488 | 273 | 1,047 | 2,808 | 222 | **3,030** |
| Research and development expenses | 216 | 56 | 1,623 | 1,895 | 237 | **2,132** |
| Amortization of intangible assets | 71 | — | — | 71 | 834 | **905** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | 362 | **362** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — | **—** |
| Other (income)/deductions––net | (342) | 2 | (21) | (361) | (501) | **(862)** |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | 6,650 | 1,168 | (2,666) | 5,152 | (1,199) | **3,953** |

See end of tables for notes (a) through (d).

| (MILLIONS OF DOLLARS) | Six Months Ended June 28, 2020 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $19,802 | $4,027 | $— | $23,829 | $— | **$23,829** |
| Cost of sales | 3,488 | 1,003 | 95 | 4,586 | 73 | **4,658** |
| % of revenue | 17.6% | 24.9% | \* | 19.2% | \* | **19.5%** |
| Selling, informational and administrative expenses | 2,980 | 560 | 2,013 | 5,553 | 350 | **5,903** |
| Research and development expenses | 401 | 110 | 3,110 | 3,622 | 234 | **3,856** |
| Amortization of intangible assets | 141 | — | — | 142 | 1,648 | **1,790** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | 431 | **431** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | (6) | **(6)** |
| Other (income)/deductions––net | (588) | (5) | 45 | (547) | (94) | **(641)** |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | 13,379 | 2,359 | (5,264) | 10,474 | (2,635) | **7,838** |

| (MILLIONS OF DOLLARS) | Second Quarter of 2019 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $9,432 | $2,970 | $862 | $13,264 | $— | **$13,264** |
| Cost of sales | 1,732 | 551 | 273 | 2,556 | 20 | **2,576** |
| % of revenue | 18.4% | 18.6% | \* | 19.3% | \* | **19.4%** |
| Selling, informational and administrative expenses | 1,685 | 385 | 1,394 | 3,464 | 48 | **3,511** |
| Research and development expenses | 200 | 60 | 1,565 | 1,825 | 16 | **1,842** |
| Amortization of intangible assets | 67 | — | — | 67 | 1,117 | **1,184** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | (115) | **(115)** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — | **—** |
| Other (income)/deductions––net | (323) | 1 | 222 | (100) | 226 | **126** |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | 6,071 | 1,973 | (2,592) | 5,452 | (1,311) | **4,141** |

| (MILLIONS OF DOLLARS) | Six Months Ended June 30, 2019 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $18,477 | $6,184 | $1,721 | $26,382 | $— | **$26,382** |
| Cost of sales | 3,374 | 1,088 | 510 | 4,971 | 38 | **5,009** |
| % of revenue | 18.3% | 17.6% | \* | 18.8% | \* | **19.0%** |
| Selling, informational and administrative expenses | 3,201 | 722 | 2,853 | 6,775 | 75 | **6,850** |
| Research and development expenses | 364 | 115 | 3,039 | 3,518 | 26 | **3,544** |
| Amortization of intangible assets | 129 | — | — | 130 | 2,237 | **2,367** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | (69) | **(69)** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — | **—** |
| Other (income)/deductions––net | (545) | 8 | 302 | (235) | 453 | **218** |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | 11,954 | 4,251 | (4,983) | 11,223 | (2,760) | **8,463** |

\* Indicates calculation not meaningful or result is equal to or greater than 100%.

(a) Amounts represent the revenues and costs managed by each of the Biopharma and Upjohn reportable operating segments for the periods presented. The expenses generally include only those costs directly attributable to the operating segment.

(b) Other comprises the revenues and costs included in our Adjusted income components (see footnote (c) below) that are managed outside Biopharma and Upjohn and includes the following:

| (MILLIONS OF DOLLARS) | Second Quarter of 2020 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $— | $— | $— |
| Cost of sales | — | — | — | 17 | 17 |
| Selling, informational and administrative expenses | 40 | — | 107 | 900 | 1,047 |
| Research and development expenses | 646 | 727 | 6 | 245 | 1,623 |
| Amortization of intangible assets | — | — | — | — | — |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | — | 5 | — | (25) | (21) |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | (685) | (732) | (113) | (1,136) | (2,666) |

| (MILLIONS OF DOLLARS) | Six Months Ended June 28, 2020 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $— | $— | $— |
| Cost of sales | (1) | 1 | — | 96 | 95 |
| Selling, informational and administrative expenses | 68 | — | 213 | 1,732 | 2,013 |
| Research and development expenses | 1,224 | 1,498 | 11 | 376 | 3,110 |
| Amortization of intangible assets | — | — | — | — | — |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | 2 | 1 | 1 | 41 | 45 |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | (1,293) | (1,499) | (226) | (2,245) | (5,264) |

| (MILLIONS OF DOLLARS) | Second Quarter of 2019 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $862 | $— | $862 |
| Cost of sales | — | 1 | 276 | (4) | 273 |
| Selling, informational and administrative expenses | 29 | — | 407 | 958 | 1,394 |
| Research and development expenses | 548 | 764 | 32 | 221 | 1,565 |
| Amortization of intangible assets | — | — | — | — | — |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | (1) | 1 | (1) | 224 | 222 |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | (576) | (765) | 148 | (1,399) | (2,592) |

83

| (MILLIONS OF DOLLARS) | Six Months Ended June 30, 2019 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $1,721 | $— | $1,721 |
| Cost of sales | — | 1 | 550 | (42) | 510 |
| Selling, informational and administrative expenses | 50 | — | 795 | 2,008 | 2,853 |
| Research and development expenses | 1,080 | 1,490 | 63 | 406 | 3,039 |
| Amortization of intangible assets | — | — | — | — | — |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | (2) | — | — | 304 | 302 |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income | (1,128) | (1,491) | 313 | (2,676) | (4,983) |

(i) WRDM—the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines.

(ii) GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.

(iii) Other—the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.

(iv) Corporate and Other Unallocated––the costs associated with corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. Corporate and Other Unallocated also includes our share of earnings from the GSK Consumer Healthcare joint venture and other charges related to the GSK Consumer Healthcare joint venture, primarily representing our pro-rata share of restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture.

We recognized the following amounts in *Cost of sales* related to forward-exchange contracts designated as cash flow hedges of a portion of our foreign exchange-denominated forecasted intercompany inventory sales:

- a $80 million net gain in the second quarter of 2020;
- a $150 million net gain in the first six months of 2020;
- a $59 million net gain in the second quarter of 2019; and
- a $103 million net gain in the first six months of 2019.

For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.*

(c) See the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A for a definition of these “Adjusted Income” components.

(d) Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities), that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP adjusted measure of performance, see the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A.

### Second Quarter of 2020 vs. Second Quarter of 2019

### Biopharma Operating Segment

Biopharma *Revenues* increased $363 million, or 4%, to $9.8 billion in the second quarter of 2020 from $9.4 billion in the second quarter of 2019, reflecting an operational increase of $593 million, or 6%, partially offset by the unfavorable impact of foreign exchange of $230 million, or 2%.

The following provides an analysis of the increase in Biopharma worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Biopharma Revenues, for the three months ended June 30, 2019 | $9,432 |
| Operational growth/(decline): |  |
| Continued growth from certain key brands(a) | 351 |
| Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU | 175 |
| Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC | 93 |
| Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit and new product launches | 78 |
| Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019 | 64 |
| Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Japan and Brazil, all of which is expected to continue | (66) |
| Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China | (28) |
| Other operational factors, net | (74) |
| Operational growth, net | 593 |
| Unfavorable impact of foreign exchange | (230) |
| Biopharma Revenues increase | 363 |
| Biopharma Revenues, for the three months ended June 28, 2020 | $9,795 |

(a) Certain key brands represent Ibrance, Eliquis and Xeljanz. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Total Biopharma revenues from emerging markets decreased $80 million, or 4%, to $1.9 billion in the second quarter of 2020 from $2.0 billion in the second quarter of 2019, reflecting operational growth of $82 million, or 4%. Foreign exchange had an unfavorable impact of 8% on total Biopharma revenues from emerging markets. The operational increase in emerging markets was primarily driven by Prevenar 13 and Eliquis, partially offset by Sulperazon.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* decreased 0.9 percentage points, driven by a favorable change in product mix, which includes an increase in alliance revenue which has no associated cost of sales, and a favorable impact of foreign exchange, partially offset by an increase in royalty expenses based on the mix of products sold.
- The decrease in *Cost of sales* of 1% was mainly driven by a favorable impact of foreign exchange, partially offset by an increase in royalty expense based on the mix of products sold, and an unfavorable change in product mix.
- The decrease in *Selling, informational and administrative expenses* of 12% was mostly driven by lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic, a favorable impact of foreign exchange, and lower investments across the Inflammation & Immunology portfolio, partially offset by additional investment in the Oncology portfolio in developed markets.
- The increase in *Research and development expenses* of 8% was mainly related to increased medical spending, primarily for Rare Disease, Internal Medicine, and Hospital.
- The favorable change in *Other (income)/deductions––net* includes, among other things, an increase in income from collaborations, out-licensing arrangements and sales of compound/product rights, partially offset by a decrease in royalty- related income mainly due to the non-recurrence of a one-time favorable resolution of a legal dispute in the second quarter of 2019.

### Upjohn Operating Segment

Upjohn *Revenues* decreased $964 million, or 32%, to $2.0 billion in the second quarter of 2020 from $3.0 billion in the second quarter of 2019, reflecting an operational decrease of $917 million, or 31%, and the unfavorable impact of foreign exchange of $48 million, or 2%.

The following provides an analysis of the decrease in Upjohn worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Upjohn Revenues, for the three months ended June 30, 2019 | $2,970 |
| Operational growth/(decline): |  |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019 | (826) |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition | (34) |
| Growth in revenues for Lipitor and Norvasc, reflecting significant revenue declines in the prior-year period associated with the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion | 55 |
| Other operational factors, net | (111) |
| Operational decline, net | (917) |
| Unfavorable impact of foreign exchange | (48) |
| Upjohn Revenues decrease | (964) |
| Upjohn Revenues, for the three months ended June 28, 2020 | $2,006 |

Total Upjohn revenues from emerging markets increased $11 million, or 1%, to $862 million in the second quarter of 2020 from $851 million in the second quarter of 2019, reflecting operational growth of $57 million, or 7%. Foreign exchange had an unfavorable impact of 5% on total Upjohn revenues from emerging markets. The operational increase in emerging markets was primarily driven by Lipitor and Norvasc in China.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* increased 6.7 percentage points, driven by lower Lyrica revenues, primarily in the U.S. due to multi-source generic competition that began in July 2019, partially offset by lower royalty expense for Lyrica due to its U.S. patent expiration.
- The decrease in *Cost of sales* of 8% was mainly driven by a decrease in sales volume and lower royalty expense primarily due to the Lyrica patent expiration and multi-source generic competition that began in the U.S. in July 2019.
- *Selling, informational and administrative expenses* decreased 29% driven by a decrease in field force expense as well as advertising and promotion expenses, primarily related to Lipitor and Norvasc, due to the volume-based procurement (VBP) program in China, which was initially implemented in certain cities in March 2019 and expanded nationwide beginning in December 2019, as well as Lyrica in the U.S. due to generic competition that began in July 2019 and anticipated generic competition for Celebrex in Japan beginning in June 2020.
- *Research and development expenses* and *Other (income)/deductions––net* were relatively unchanged.

### First Six Months of 2020 vs. First Six Months of 2019

### Biopharma Operating Segment

Biopharma *Revenues* increased $1.3 billion, or 7%, to $19.8 billion in the first six months of 2020 from $18.5 billion in the first six months of 2019, reflecting an operational increase of $1.7 billion, or 9%, and an unfavorable impact of foreign exchange of $345 million, or 2%.

The following provides an analysis of the increase in Biopharma worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Biopharma Revenues, for the six months ended June 30, 2019 | $18,477 |
| Operational growth/(decline): |  |
| Continued growth from certain key brands(a) | 812 |
| Higher revenues for the rare disease business driven by the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019 for ATTR-CM; and in international markets, primarily driven by the March 2019 launch of the ATTR-CM indication in Japan and the February 2020 approval of the ATTR-CM indication in the EU | 353 |
| Higher revenues for the Hospital business in the U.S., primarily driven by increased demand for certain sterile injectable products utilized in the intubation and ongoing treatment of mechanically-ventilated COVID-19 patients as well as continued growth from Panzyga following its November 2018 U.S. launch | 212 |
| Higher revenues for Inlyta, primarily in the U.S., driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC | 191 |
| Higher revenues for Biosimilars, primarily in the U.S., driven by strong volume performance from Retacrit, new product launches and steady volume and share growth in the U.S. for Inflectra, across hospital channels, clinics and alternate sites of care | 190 |
| Higher revenues for Xtandi primarily driven by continued strong demand in the metastatic and non-metastatic castration-resistant prostate cancer indications as well as the metastatic (mCSPC) castration-sensitive prostate cancer indication, which was approved in the U.S. in December 2019 | 106 |
| Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Brazil and Japan, all of which is expected to continue | (159) |
| Decline in Prevnar 13/Prevenar 13 revenues primarily in the U.S., reflecting the expected unfavorable impact of disruptions to wellness visits for pediatric and adult patients due to COVID-19-related mobility restrictions or limitations, partially offset by the favorable impact of timing associated with government purchases for the pediatric indication, compared to the prior-year period. The decline in the U.S. was partially offset by growth in international markets primarily reflecting significantly increased adult uptake in Germany and certain other markets resulting from greater vaccine awareness for respiratory illnesses, including specifically pneumococcal disease, due to the COVID-19 pandemic, as well as continued strong pediatric uptake in China | (47) |
| Other operational factors, net | 11 |
| Operational growth, net | 1,670 |
| Unfavorable impact of foreign exchange | (345) |
| Biopharma Revenues increase | 1,325 |
| Biopharma Revenues, for the six months ended June 28, 2020 | $19,802 |

(a) Certain key brands represent Ibrance, Eliquis and Xeljanz. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Total Biopharma revenues from emerging markets increased $143 million, or 4%, to $4.1 billion in the first six months of 2020 from $3.9 billion in the first six months of 2019, reflecting operational growth of $379 million, or 10%. Foreign exchange had an unfavorable impact of 6% on total Biopharma revenues from emerging markets. The operational increase in emerging markets was primarily driven by Prevenar 13, Eliquis, certain anti-infective products, primarily Zavicefta and Zithromax, Ibrance and Xalkori, partially offset by Sulperazon.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* decreased 0.6 percentage points, driven by a favorable change in product mix, which includes an increase in alliance revenue which has no associated cost of sales, partially offset by an increase in royalty expenses based on the mix of products sold.
- The increase in *Cost of sales* of 3% was mainly driven by an increase in sales volumes for various products and an increase in royalty expenses based on the mix of products sold, partially offset by a favorable impact of foreign exchange.
- The decrease in *Selling, informational and administrative expenses* of 7% was mostly driven by lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic, lower investments across the Inflammation & Immunology portfolio, a favorable impact of foreign exchange, and lower healthcare reform expenses, partially offset by additional investment in the Oncology portfolio in developed markets.
- The increase in *Research and development expenses* of 10% was mainly related to increased medical spending, primarily for Oncology, Internal Medicine, and Rare Disease.
- The favorable change in *Other (income)/deductions––net* includes, among other things, an increase in income from collaborations, out-licensing arrangements and sales of compound/product rights, partially offset by a decrease in royalty- related income mainly due to the non-recurrence of a one-time favorable resolution of a legal dispute in the second quarter of 2019.

### Upjohn Operating Segment

Upjohn *Revenues* decreased $2.2 billion, or 35%, to $4.0 billion in the first six months of 2020 from $6.2 billion in the first six months of 2019, reflecting an operational decrease of $2.1 billion, or 34%, and the unfavorable impact of foreign exchange of $66 million, or 1%.

The following provides an analysis of the decrease in Upjohn worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Upjohn Revenues, for the six months ended June 30, 2019 | $6,184 |
| Operational decline: |  |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in the U.S. in July 2019 | (1,655) |
| Declines in revenues for Lipitor and Norvasc, primarily resulting from the VBP program in China, which was initially implemented in certain cities in March 2019, and expanded nationwide beginning in December 2019, resulting in significant volume and price erosion | (254) |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to multi-source generic competition | (58) |
| Other operational factors, net | (124) |
| Operational decline, net | (2,090) |
| Unfavorable impact of foreign exchange | (66) |
| Upjohn Revenues decrease | (2,156) |
| Upjohn Revenues, for the six months ended June 28, 2020 | $4,027 |

Total Upjohn revenues from emerging markets decreased $307 million, or 15%, to $1.7 billion in the first six months of 2020 from $2.0 billion in the first six months of 2019, reflecting an operational decline of $247 million or, 12%, and the unfavorable impact of foreign exchange of 3% on total Upjohn revenues from emerging markets. The operational decline in emerging markets was primarily driven by Lipitor and Norvasc in China.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* increased 7.3 percentage points, driven by lower Lyrica revenues, primarily in the U.S. due to multi-source generic competition that began in July 2019, lower Lipitor and Norvasc revenues due to the VBP program in China, which was initially implemented in March 2019 and expanded nationwide beginning in December 2019, and an unfavorable impact of foreign exchange, partially offset by lower royalty expense for Lyrica due to its U.S. patent expiration.
- The decrease in *Cost of sales* of 8% was mainly driven by lower royalty expense and a decrease in sales volume primarily due to the Lyrica patent expiration and multi-source generic competition that began in the U.S. in July 2019.
- *Selling, informational and administrative expenses* decreased 22% driven by a reduction in field force expense as well as advertising and promotion expenses, primarily related to Lyrica in the U.S. due to generic competition that began in July 2019 and the anticipated generic competition for Celebrex in Japan that began in June 2020, as well as a decrease in Lipitor and Norvasc expenses due to the VBP program in China, which was initially implemented in certain cities in March 2019 and expanded nationwide beginning in December 2019.
- *Research and development expenses* and *Other (income)/deductions––net* were relatively unchanged.

### ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

| (MILLIONS OF DOLLARS) Cash provided by/(used in): | Six Months Ended June 28, 2020 | June 30, 2019 | % Change |
| --- | ---: | ---: | --- |
| Operating activities | $6,688 | $4,309 | 55 |
| Investing activities | (13,082) | 5,648 | \* |
| Financing activities | 6,959 | (9,318) | \* |
| Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents | (70) | (28) | \* |
| Net increase in Cash and cash equivalents and restricted cash and cash equivalents | $495 | $612 | (19) |
| \* Calculation not meaningful or results are equal to or greater than 100%. |  |  |  |

88

### Operating Activities

The increase in net cash provided by operating activities is driven by the net change in *Other changes in assets and liabilities, net of acquisitions and divestitures*, partially offset by a decrease in net income, reflecting the lower contribution from the Consumer Healthcare business as a result of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK.

In the first six months of 2020, the change in the line item *Other adjustments, net* primarily reflects, among other items:

- an increase in equity method dividends received,

partially offset by:

- an increase in net unrealized gains on equity securities;
- an increase in equity income; and
- an increase in accreted interest on debt discount.

In the condensed consolidated statements of cash flows, the line item *Other changes in assets and liabilities, net of acquisitions and divestitures* is presented excluding the effects of changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or outflows, and excluding any other significant non-cash movements. Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our condensed consolidated balance sheets. In the first six months of 2020 and 2019, the line item *Other changes in assets and liabilities, net of acquisitions and divestitures,* primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current and noncurrent assets, trade accounts payable, accrued compensation, and other current and noncurrent liabilities, as well as in 2019, the adjustment necessary to reflect the non-cash nature of the favorable settlement of an IRS audit for multiple tax years (see Notes to Consolidated Financial Statements––*Note 5D. Tax Matters: Tax Contingencies* in our 2019 Financial Report).

### Investing Activities

The change in net cash provided by/(used in) investing activities was mostly attributable to:

- a $16.7 billion increase in net purchases of short-term investments with original maturities of three months or less, largely due to the $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which were invested in money market funds (see Notes to Condensed Consolidated Financial Statements—*Note 7D. Financial Instruments: Long-Term Debt* and —*Note 7A. Financial Instruments: Fair Value Measurements*); and
- a $1.4 billion decrease in proceeds from redemptions and sales of short-term investments.

### Financing Activities

The change in net cash provided by/(used in) financing activities was primarily attributable to:

- an increase in issuances of long-term debt of $11.7 billion (see Notes to Condensed Consolidated Financial Statements—*Note 7D. Financial Instruments: Long-Term Debt);*
- a decrease in purchases of common stock of $8.9 billion; and
- lower repayments on long-term debt of $3.2 billion,

partially offset by:

- $3.1 billion net payments on short-term borrowings in the first six months of 2020, compared to $4.3 billion net proceeds raised from short-term borrowings in the first six months of 2019.

### ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. We continue our efforts to improve cash inflows through working capital efficiencies. We target specific areas of focus including accounts receivable, inventories, accounts payable, and other working capital, which allows us to optimize our operating cash flows. Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future, which can include, among others:

- the working capital requirements of our operations, including our R&D activities;
- investments in our business;
- dividend payments and potential increases in the dividend rate;
- share repurchases;
- the cash requirements associated with our cost-reduction/productivity initiatives;
- paying down outstanding debt;
- contributions to our pension and postretirement plans; and
- business-development activities.

Our long-term debt is rated high-quality by both S&P and Moody’s. See the “Credit Ratings” section below. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term debt investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.

### Selected Measures of Liquidity and Capital Resources

*The following table provides certain relevant measures of our liquidity and capital resources:*

| (MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON SHARE DATA) Selected financial assets(a): | June 28, 2020 | December 31, 2019 |
| --- | ---: | ---: |
| Cash and cash equivalents | $1,801 | $1,305 |
| Restricted short-term investments | 11,412 | — |
| Short-term investments | 9,581 | 8,525 |
| Long-term investments, excluding private equity securities at cost | 2,370 | 2,258 |
|  | 25,163 | 12,088 |
| Debt: |  |  |
| Short-term borrowings, including current portion of long-term debt | 13,084 | 16,195 |
| Long-term debt | 50,529 | 35,955 |
|  | 63,613 | 52,150 |
| Selected net financial liabilities | $(38,450) | $(40,062) |
| Working capital(b) | $13,701 | $(4,501) |
| Ratio of current assets to current liabilities | 1.42:1 | 0.88:1 |
| Total Pfizer Inc. shareholders’ equity per common share(c) | $11.58 | $11.41 |

(a) See Notes to Condensed Consolidated Financial Statements––*Note 7. Financial Instruments* for a description of certain assets held and for a description of credit risk related to our financial instruments held.

(b) The increase in working capital was primarily due to:

- an increase mainly driven by operating cash flow generation and the long-term debt issuances discussed below, partially offset by debt repayment and capital expenditures; and
- the timing of accruals, cash receipts and payments in the ordinary course of business.

(c) Represents total Pfizer Inc. shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury stock).

In June 2020, Upjohn Inc. and Upjohn Finance B.V. (a wholly-owned subsidiary of Upjohn Inc.) completed privately placed debt offerings of $7.45 billion and €3.60 billion aggregate principal senior unsecured notes, respectively (the Upjohn Debt Transactions). See the “Agreement to Combine Upjohn with Mylan” section below for the discussion on the use of proceeds.

In May 2020, we completed a public offering of $4.0 billion aggregate principal amount of senior unsecured notes.

In March 2020, we:

- completed a public offering of $1.25 billion aggregate principal amount of senior unsecured sustainability notes. The proceeds were initially used to repay outstanding commercial paper and subsequently will be used to help manage our environmental impact and support increased patient access to our medicines and vaccines, especially among underserved populations, and strengthen healthcare systems; and
- repurchased at par all $1.065 billion principal amount outstanding of senior unsecured notes that were due in 2047 before the maturity date, which did not have a material impact on our condensed consolidated financial statements.

For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 7D. Financial Instruments: Long-Term Debt.*

For additional information about the sources and uses of our funds, see the “Analysis of the Condensed Consolidated Statements of Cash Flows” section of this MD&A.

#### Agreement to Combine Upjohn with Mylan

In connection with our agreement to combine Upjohn with Mylan to form a new company, Viatris, discussed in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business Development Initiatives” section of this MD&A, in June 2020, Upjohn Inc. (i) incurred $11.4 billion of debt in the Upjohn Debt Transactions, (ii) entered into a revolving credit agreement for up to $4 billion, $1.5 billion of which will be available in a single draw at or around the closing of the combination of Upjohn with Mylan for the sole purpose of funding the cash payment of $12 billion by Upjohn Inc. to Pfizer as partial consideration for Pfizer’s contribution of the Upjohn Business to Upjohn Inc. and (iii) entered into a $600 million delayed draw term loan agreement. Immediately prior to the proposed distribution to Pfizer’s stockholders of all of the issued and outstanding shares of Upjohn Inc.’s common stock held by Pfizer (the Distribution), Upjohn Inc. will make a cash distribution of $12 billion to Pfizer. The proceeds of the revolving credit agreement, term loan agreement and the Upjohn Debt Transactions will be used to fund the $12 billion cash distribution from Upjohn Inc. to Pfizer prior to the Distribution. In the interim, the $11.4 billion of proceeds from the Upjohn Debt Transactions were invested by Upjohn Inc. in money market funds and classified as *Restricted short-term investments* in the condensed consolidated balance sheet as of June 28, 2020. Upon completion of the Upjohn Debt Transactions on June 23, 2020, the commitments under the senior unsecured $12 billion bridge facility were fully terminated. Pfizer has guaranteed the notes in the Upjohn Debt Transactions, and such guarantees will automatically and unconditionally terminate without the consent of holders of the notes upon the Distribution. Upjohn Inc. has guaranteed the notes issued by Upjohn Finance B.V., and Upjohn Inc. will remain a guarantor of such notes post Distribution. Following the separation, Upjohn Inc. and Upjohn Finance B.V., as applicable, will remain the obligor with respect to all of the aforementioned debt. See Notes to Condensed Consolidated Financial Statements––*Note 7D. Financial Instruments: Long-Term Debt* for additional information.

#### Domestic and International Selected Financial Assets

Many of our operations are conducted outside the U.S., and significant portions of our selected financial assets are held internationally. The amount of funds held in U.S. tax jurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). The changes in tax law under the TCJA, which includes transitioning U.S. international taxation from a worldwide tax system to a territorial tax system, allow us to more easily access our selected financial assets globally.

#### Credit Ratings

Two major corporate debt-rating organizations, Moody’s and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.

In June 2019, S&P placed Pfizer on “CreditWatch Negative” following the announcement of Pfizer’s intention to acquire Array. The CreditWatch placement was resolved with a one-notch downgrade of Pfizer’s debt rating to ‘AA-’ upon the consummation of the transaction. In July 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, which resulted in actions from both Moody’s and S&P. Moody’s placed Pfizer’s long-term rating under review for downgrade (limited to one-notch, or ‘A2’ upon close of the Mylan transaction) while S&P lowered Pfizer’s rating to ‘AA-’ (as a result of the Array transaction) and confirmed it will still remain on CreditWatch Negative (with the expectation the rating will be lowered one additional notch to ‘A+’ upon close of the Mylan transaction).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured long-term debt: |  |  |  |  |  |  |
| NAME OF RATING AGENCY |  | Pfizer Commercial Paper |  | Pfizer Long-Term Debt | Outlook/Watch | Date of Last Rating Change |
|  | Rating |  | Rating |  |  |  |
| Moody’s |  | P-1 |  | A1 | Under Review for Downgrade | October 2009 |
| S&P |  | A-1+ |  | AA- | CreditWatch Negative | July 2019 |

#### Debt Capacity––Lines of Credit

We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings. As of June 28, 2020, we had access to a total of $15 billion in U.S. revolving credit facilities consisting of a $7 billion facility expiring in 2024 and an $8 billion facility expiring in September 2020, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional $611 million in lines of credit, of which $582 million expire within one year. Of these total lines of credit, $15.6 billion were unused as of June 28, 2020.

#### LIBOR

From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. The U.K. Financial Conduct Authority announced in July 2017 that it will no longer compel banks to submit rates that are currently used to calculate LIBOR after 2021. Various governing parties, including government agencies, are working on a benchmark transition plan for LIBOR (and other interbank offered rates globally). We are monitoring their progress, and we will likely amend contracts to accommodate any replacement rate where it is not already provided. We do not expect the transition to an alternative rate to have a material impact on our liquidity or financial resources.

#### Global Economic Conditions––General

The global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions. For additional information see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––The Global Economic Environment” section in this MD&A.

#### Global Economic Conditions––Venezuela and Argentina Operations

Our Venezuela and Argentina operations function in hyperinflationary economies. The impact to Pfizer is not considered material.

#### Off-Balance Sheet Arrangements

In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnification obligations generally are subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of June 28, 2020, the estimated fair value of our indemnification obligations was not significant.

Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.

#### Share-Purchase Plans and Accelerated Share Repurchase Agreements

At June 28, 2020, our remaining share-purchase authorization was approximately $5.3 billion, with no repurchases in the first six months of 2020 and no repurchases currently planned for the remainder of 2020. See Notes to Consolidated Financial Statements––*Note 12. Equity* in our 2019 Financial Report for more information on our publicly announced share-purchase plans, including our accelerated share repurchase agreements.

#### Dividends on Common Stock

For quarterly cash dividend information, see Notes to Condensed Consolidated Financial Statements––*Note 11. Equity.*

Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our businesses. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer’s Board of Directors and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. Also, assuming Upjohn is spun off, Pfizer expects that immediately following the closing of the proposed transaction to combine Upjohn with Mylan, the combined dividend dollar amount received by Pfizer shareholders, based upon the combination of continued Pfizer ownership and approximately 0.12 shares of the new company (Viatris) expected to be granted for each Pfizer share in a spin-off, will equate to Pfizer’s dividend amount in effect immediately prior to closing.

### NEW ACCOUNTING STANDARDS

#### Recently Adopted Accounting Standards

See Notes to Condensed Consolidated Financial Statements––*Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2020.*

|  |  |  |
| --- | --- | --- |
| Recently Issued Accounting Standards, Not Adopted as of June 28, 2020 |  |  |
| **Standard/Description** | **Effective Date** | **Effect on the Financial Statements or Other Significant Matters** |
| In December 2019, the FASB issued new guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. | January 1, 2021. Early adoption is permitted. | We do not expect this guidance to have a material impact on our consolidated financial statements. |
| In March 2020, the FASB issued new guidance to address reference rate reform by providing temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform. The new guidance provides the following optional expedients: 1. Simplify accounting analyses under current U.S. GAAP for contract modifications. 2. Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue. 3. Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform. | Elections can be adopted prospectively at any time in the first quarter of 2020 through December 31, 2022. | We are assessing the impact of the provisions of this new guidance on our consolidated financial statements. |

### FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS

This report and other written or oral statements that we make from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, plans for and prospects of our acquisitions and other business-development activities, benefits anticipated from the reorganization of our commercial operations in 2019, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, government regulation, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply, our efforts to respond to COVID-19, our expectations regarding the impact of COVID-19 on our business, operations and financial results and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions, including, among others, the expected timing of closing of and costs associated with the pending transaction to combine Upjohn with Mylan to create a new global pharmaceutical company set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business Development Initiatives” section of this MD&A, the expected impact of patent expiries on our business set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––Industry-Specific Challenges––Intellectual Property Rights and Collaboration/Licensing Rights” and “––Our Strategy––Organizing for Growth” sections of this MD&A, our efforts to respond to COVID-19, including, among other things, expectations regarding our investigational vaccine candidate against SARS-CoV-2 and our investigational protease inhibitor, and the anticipated impact of COVID-19 on our business, operations and financial results set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––The Global Economic Environment” and “––Our Financial Guidance for 2020” sections of this MD&A, the benefits expected from the reorganization of our commercial operations in 2019 and our expectations regarding growth set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy––Organizing for Growth” section of this

MD&A, the anticipated costs and savings from certain of our initiatives, primarily from our Transforming to a More Focused Company program, set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook—Our Strategy—Transforming to a More Focused Company” and “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” sections of this MD&A and in Notes to Condensed Consolidated Financial Statements––*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives*, the financial guidance set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Financial Guidance for 2020” section of this MD&A, the expected impact of ACIP’s latest recommendation for Prevnar 13 for adults 65 and older on Prevnar 13’s revenues set forth in the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion––Prevnar 13/Prevenar 13” section of this MD&A, our anticipated liquidity position set forth in the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this MD&A, our expectations regarding dividends set forth in the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this MD&A and the benefits expected from our business development transactions and the contributions that we expect to make from our general assets to the company’s pension and postretirement plans during 2020 set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Financial Guidance for 2020” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 10. Pension and Postretirement Benefit Plans*. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

- the outcome of R&D activities, including, without limitation, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new clinical data and further analyses of existing clinical data;
- the risk we may not be able to successfully address all of the comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators, which will depend on myriad factors, including such regulator making a determination as to whether a product’s benefits outweigh its known risks and a determination of the product’s efficacy; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; and recommendations by technical or advisory committees, such as ACIP, that may impact the use of our vaccines;
- the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;
- claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of, a product that could affect its availability or commercial potential, such as the update to the U.S. and EU prescribing information for Xeljanz;
- the success of external business-development activities, including the ability to identify and execute on potential business development opportunities, the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all, the ability to realize the anticipated benefits of any such transactions, and the potential need to obtain additional equity or debt financing to pursue these opportunities, which could result in increased leverage and impact our credit ratings;
- competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;
- the implementation by the FDA and regulatory authorities in certain countries of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;
- risks related to our ability to develop and commercialize biosimilars, including risks associated with “at risk” launches, defined as the marketing of a product by Pfizer before the final resolution of litigation (including any appeals) brought by a third party alleging that such marketing would infringe one or more patents owned or controlled by the third party, and access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the innovator product;
- the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent protection for our products or competitor products;
- the ability to successfully market both new and existing products domestically and internationally;
- difficulties or delays in manufacturing, sales or marketing, including delays caused by natural events, such as hurricanes; supply disruptions, shortages or stock-outs at our facilities; and legal or regulatory actions, such as

warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, recall of a product, delays or denials of product approvals, import bans or denial of import certifications;

- the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic) on our business, operations and financial condition and results, including due to travel limitations and government-mandated work-from-home or shelter-in-place orders, manufacturing disruptions or delays, supply chain interruptions, including challenges related to reliance on third-party suppliers, disruptions to pipeline development and clinical trials, including difficulties or delays in enrollment of certain clinical trials, decreased product demand, including due to reduced numbers of in-person meetings with prescribers, patient visits with physicians, vaccinations and elective surgeries resulting in fewer new prescriptions or refills of existing prescriptions and reduced demand for products used in procedures, further reduced product demand as a result of increased unemployment, challenges presented by reallocating human capital, R&D, manufacturing and other resources to assist in responding to the pandemic without disruption to our operations, costs associated with the COVID-19 pandemic, including protocols intended to reduce the risk of transmission, increased supply chain costs and additional R&D costs incurred in our efforts to develop a potential vaccine and treatment for COVID-19, challenges related to our business development initiatives, including potential delays or disruptions related to regulatory approvals, including the anticipated combination of Upjohn with Mylan, interruptions or delays in the operations of certain regulatory authorities, which may delay the approvals of new products we are developing, potential label expansions for existing products and the launch of newly-approved products, potential increased cyber incidents such as phishing, social engineering and malware attacks, and other challenges presented by disruptions to our normal operations in response to the pandemic, as well as uncertainties regarding the duration and severity of the pandemic and its impacts and government or regulatory actions to contain the virus or control the supply of medicines, each of which may also amplify the impact of the other factors listed in this section;
- uncertainties related to our efforts to develop a potential treatment or vaccine for COVID-19, including uncertainties related to the risk that our development programs may not be successful, commercially viable or receive approval or Emergency Use Authorization from regulatory authorities, risks associated with preliminary data, including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data that may be inconsistent with the data used for selection of the BNT162b2 vaccine candidate and dose level for the Phase 2/3 study, the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities, whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications, disruptions in the relationships between us and our collaboration partners or third-party suppliers, the risk that other companies may produce superior or competitive products, the risk that demand for any products may no longer exist, risks related to the availability of raw materials to manufacture any such products, the risk that we may not be able to recoup costs associated with our R&D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development related to COVID-19, the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated, and pricing and access challenges for such products, including in the U.S.;
- trade buying patterns;
- the impact of existing and future legislation and regulatory provisions on product exclusivity;
- trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;
- the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;
- the impact of any U.S. healthcare reform or legislation, including any replacement, repeal, modification or invalidation of some or all of the provisions of the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act;
- U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases that could result in new mandatory rebates and discounts or other pricing restrictions; general budget control actions; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; revisions to reimbursement of biopharmaceuticals under

government programs; restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;

- legislation or regulatory action in markets outside the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;
- the exposure of our operations outside the U.S. to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;
- contingencies related to actual or alleged environmental contamination;
- any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;
- legal defense costs, insurance expenses and settlement costs;
- the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment and other legal proceedings, including various means for resolving asbestos litigation, as well as tax issues;
- the risk that our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis, or any patent-term extensions that we seek may not be granted on a timely basis, if at all;
- our ability to protect our patents and other intellectual property, both domestically and internationally, including against claims of invalidity that could result in loss of exclusivity, such as claims related to our Lyrica patents in Japan, and in response to any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection for or agreeing not to enforce intellectual property related to our medicines, including potential vaccines and treatments for COVID-19;
- interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;
- governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals, including further clarifications and/or interpretations of or changes to the TCJA enacted in 2017;
- any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;
- the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines;
- uncertainties based on the formal change in relationship between the U.K. government and the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products;
- any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal or regulatory requirements and industry standards;
- any significant issues that may arise related to our joint ventures and other third-party business arrangements;
- further clarifications and/or changes in interpretations of existing laws and regulations, or changes in laws and regulations, in the U.S. and other countries, including changes in U.S. generally accepted accounting principles;
- uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; the related risk that our allowance for doubtful accounts may not be adequate; and the risks related to volatility of our income due to changes in the market value of equity investments;
- any changes in business, political and economic conditions due to actual or threatened terrorist activity or civil unrest in the U.S. and other parts of the world, and related U.S. military action overseas;
- growth in costs and expenses;
- changes in our product, segment and geographic mix;
- the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;
- the impact of product recalls, withdrawals and other unusual items;
- the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;
- the impact of, and risks and uncertainties related to, acquisitions and divestitures, such as the acquisition of Array, our transaction with GSK which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture and our agreement to combine Upjohn with Mylan to create a new global pharmaceutical company, Viatris, including, among other things, risks related to the satisfaction of the conditions to closing to any pending transaction (including the failure to obtain any necessary shareholder and regulatory approvals) in the anticipated timeframe or at all and the possibility that such transaction does not close; the ability to realize the anticipated benefits of those transactions, including the possibility that the expected cost savings and/or accretion from certain of those transactions will not be realized or will not be realized within the expected time frame; the risk that the businesses will not be integrated successfully; negative effects of the announcement or the consummation of the transaction on the market price of Pfizer’s common stock, Pfizer’s credit ratings and/or Pfizer’s operating results; disruption from the transactions making it more difficult to maintain business and operational relationships; risks related to our ability to grow revenues for certain acquired products; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the transaction, other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, changes in tax and other laws, regulations, rates and policies, future business combinations or disposals; competitive developments; and as it relates to the Consumer Healthcare JV with GSK, the possibility that a future separation of the joint venture as an independent company via a demerger of GSK’s equity interest to GSK’s shareholders and a listing of the joint venture on the U.K. equity market may not occur; and
- the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, including the reorganization of our commercial operations in 2019, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption.

We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are cautioned not to put undue reliance on forward-looking statements.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects.

Additional discussion regarding certain risks, uncertainties and assumptions described above, as well as other material risks to our business, is included under the heading entitled “Risk Factors” in Part I, Item 1A. of our 2019 Form 10-K and Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q. These risks could cause actual results to differ materially from past and projected future results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. We incorporate that section of the 2019 Form 10-K in this filing and investors should refer to it. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

The operating segment information provided in this report does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.

This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

## Market risk

As filed, 214 characters.

Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk—Financial Risk Management”, of our 2019 Form 10-K.

## Controls and procedures

As filed, 983 characters.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.

During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 7,360 characters.

We refer to the “Our Operating Environment”, “The Global Economic Environment” and “Forward-Looking Information and Factors That May Affect Future Results” sections of the MD&A of this Quarterly Report on Form 10-Q and Part I, Item 1A, “Risk Factors” of our 2019 Form 10-K. We are including the following risk factor, which should be read in conjunction with the risk factors discussed in Part I, Item 1A, “Risk Factors” of our 2019 Form 10-K.

### COVID-19 PANDEMIC

Our business, operations and financial condition and results have been and may continue to be impacted by the COVID-19 pandemic to varying degrees. We currently anticipate an ongoing, gradual global recovery from the first-half 2020 macroeconomic and healthcare impacts of the COVID-19 pandemic beginning in the third quarter of 2020. The pandemic continues to present a number of risks and challenges for our business, including, among others, impacts due to travel limitations and government-mandated work-from-home or shelter-in-place orders; manufacturing disruptions and delays; supply chain interruptions, including challenges related to reliance on third-party suppliers; disruptions to pipeline development and clinical trials, including difficulties or delays in enrollment of certain clinical trials; decreased product demand, including due to reduced numbers of in-person meetings with prescribers, patient visits with physicians, vaccinations and elective surgeries resulting in fewer new prescriptions or refills of existing prescriptions and reduced demand for products used in procedures; further reduced product demand as a result of increased unemployment; challenges presented by reallocating human capital, R&D, manufacturing and other resources to assist in responding to the pandemic without disruption to our operations; costs associated with the COVID-19 pandemic, including protocols intended to reduce the risk of transmission; increased supply chain costs and additional R&D costs incurred in our efforts to develop a vaccine and treatment for COVID-19; challenges related to our business development initiatives, including potential delays or disruptions related to regulatory approvals, including the anticipated combination of Upjohn with Mylan; interruptions or delays in the operations of certain regulatory authorities, which may delay the approvals of new products we are developing, potential label expansions for existing products and the launch of newly-approved products; potential increased cyber incidents such as phishing, social engineering and malware attacks; challenges related to our intellectual property, both domestically and internationally, including in response to any pressure or legal or regulatory action, by various stakeholders or governments that could potentially result in us not seeking intellectual property protection for, licensing or agreeing not to enforce our intellectual property rights related to our medicines, including potential vaccines and treatments for COVID-19; and other challenges presented by disruptions to our normal operations in response to the pandemic, as well as uncertainties regarding the duration and severity of the pandemic and its impacts and government or regulatory actions to contain the virus or control the supply of medicines.

We also face uncertainties related to our efforts to develop a potential treatment or vaccine for COVID-19, including uncertainties related to the risk that our development programs may not be successful, commercially viable or receive approval or Emergency Use Authorization from regulatory authorities; risks associated with preliminary data, including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data that may be inconsistent with the data used for selection of the BNT162b2 vaccine candidate and dose level for the Phase 2/3 study; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; disruptions in the relationships between us and our collaboration partners or third-party suppliers; the risk that other companies may produce superior or competitive products; the risk that demand for any products we may develop may no longer exist; risks related to the availability of raw materials to manufacture any such products; the risk that we may not be able to recoup costs associated with our R&D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development related to COVID-19; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; and pricing and access challenges for such products, including in the U.S.

Further, the COVID-19 pandemic, and the volatile global economic conditions stemming from the pandemic, could precipitate or amplify the other risk factors that we identify in the “Risk Factors” section of our 2019 Form 10-K, which could materially adversely affect our business, operations and financial condition and results.

We are continuing to monitor the latest developments regarding the COVID-19 pandemic on our business, operations and financial condition and results, and have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration and severity of the pandemic and the global macroeconomic impact of the pandemic. Despite careful tracking and planning, however, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. In particular, we believe the ultimate impact on our business, operations and financial condition and results will be affected by the speed and extent of the continued spread of the coronavirus globally, the duration of the pandemic, new information that may emerge concerning the severity and incidence of COVID-19, the safety, efficacy and availability of a vaccine and treatments for COVID-19, the global macroeconomic impact of the pandemic and governmental or regulatory actions to contain the virus or control supply of medicines. The pandemic may also affect our business, operations or financial condition and results in a manner that is not presently known to us or that we currently do not consider to present significant risks.

For additional information on how the COVID-19 pandemic has already impacted our business, operations and financial condition and results, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––The Global Economic Environment” section of the MD&A of this Quarterly Report on Form 10-Q.

Filed Aug 6, 2020.
Source: SEC EDGAR, the filing index for accession 0000078003-20-000060. Last ingested by Listed: Nov 12, 2026, 18:08 ET. No prices; not investment advice.
